A Western Dietary Pattern during Pregnancy is Associated with Neurodevelopmental Disorders

in Childhood and Adolescence

David Horner MD MSc[1], Jens Richardt M. Jepsen, MSc PhD[2+3], Bo Chawes, MD PhD DMSc[1], Kristina

Aagaard MD[1], Julie B. Rosenberg MD[1+2+4], Parisa Mohammadzadeh MD[1+2+4], Astrid Sevelsted MSc

PhD[1], Nilo Følsgaard MD PhD[1], Rebecca Vinding MD PhD[1], Birgitte Fagerlund PhD[2+5], Christos Pantelis

MBBS MD[6+7], Niels Bilenberg MD PhD[8], Casper-Emil T. Pedersen, MSc PhD[1], Anders Eliasen MD,

PhD[1+9], Yulu Chen, PhD[10], Nicole Prince, PhD[10], Su H. Chu, PhD[10], Rachel S. Kelly, PhD[10], Jessica

Lasky-Su, ScD[10], Thorhallur I. Halldorsson, PhD[11+12], Marin Strøm, PhD[12+13], Katrine Strandberg-Larsen,

PhD[14], Sjurdur F. Olsen, PhD[12+13+14+15], Birte Y. Glenthøj, MD DMSc[2+4], Klaus Bønnelykke, MD PhD[1],

Bjørn H. Ebdrup*, MD PhD[2+4], Jakob Stokholm*, MD PhD[1+16], Morten Arendt Rasmussen*, PhD[1+16]

*These authors contributed equally to this work

Affiliations:

1) COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital,

University of Copenhagen, Denmark

2) Center for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and

Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of

Copenhagen, Glostrup, Denmark

3) Mental Health Centre for Child and Adolescent Psychiatry - Research unit, Mental Health Services in the

Capital Region of Denmark, Copenhagen, Denmark

4) Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,

Copenhagen, Denmark

5) Department of Psychology, University of Copenhagen, Copenhagen, Denmark

6) Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne

Health, Carlton South, VIC, Australia

7) Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia

8) Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

9) Department of Health Technology, Section for Bioinformatics, Technical University of Denmark, Kgs.

Lyngby, Denmark

10) Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

11) Faculty of Food Science and Nutrition, School of Health Science, University of Iceland, Health Science Institute, Unit for Nutrition Research, Iceland

12) Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

13) Faculty of Health Sciences, University of the Faroe Islands, Tórshavn, Faroe Islands

14) Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark

15) Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

16) Section of Food Microbiology, Gut Health and Fermentation, Department of Food Science, University of Copenhagen, Denmark

ABSTRACT

Despite the high prevalence of neurodevelopmental disorders, there is a notable gap in clinical studies

exploring the impact of maternal diet during pregnancy on child neurodevelopment. This observational

clinical study examined the association between pregnancy dietary patterns and neurodevelopmental

disorders, as well as their symptoms, in a prospective cohort of 10-year-old children (n=508). Data-

driven dietary patterns were derived from self-reported food frequency questionnaires. A Western

dietary pattern in pregnancy (per SD change) was significantly associated with attention-deficit /

hyperactivity disorder (ADHD) (OR 1.66 [1.21 - 2.27], p=0.002) and autism diagnosis (OR 2.22 [1.33 -

3.74], p=0.002) and associated symptoms (p<0.001). Findings for ADHD were validated in three large

(n=59725, n=656, n=348), independent mother-child cohorts. Objective blood metabolome modelling

at 24 weeks gestation identified 15 causally mediating metabolites which significantly improved ADHD

prediction in external validation. Temporal analyses across five blood metabolome timepoints in two

independent mother-child cohorts revealed that the association of Western dietary pattern metabolite

scores with neurodevelopmental outcomes was consistently significant in early to mid-pregnancy,

independent of later child timepoints. These findings underscore the importance of early intervention

and provide robust evidence for targeted prenatal dietary interventions to prevent neurodevelopmental

disorders in children.

INTRODUCTION

Neurodevelopmental disorders, particularly attention-deficit/hyperactivity disorder (ADHD) and autism, are prevalent and an increasing public health concern (1). In 2020, Danish registers reported a cumulative incidence of 5.9% in males and 3% in females for ADHD, and 4.3% in males and 1.8% in females for autism during childhood and adolescence (2). Large meta-analyses support these findings, with global estimates of 5.9% for ADHD (3) and up to 1.1% for autism (4). In addition, neurodevelopmental disorder symptoms manifest as continuous traits within the paediatric general population (5), and can be reliably captured via validated questionnaires (6,7). Studies have linked several prenatal exposures to neurodevelopmental disorders in children, including maternal obesity, metabolic disturbances, stress, and individual nutritional elements (8). Numerous animal studies have shown that high-fat diets can alter brain morphology (9) and behaviour in offspring in ways resembling neurodevelopmental disorders (10,11), however these findings may not extrapolate well to humans. Dietary constituents may contribute directly to the aforementioned aetiologies, providing both the energy substrates and building blocks for the foetal brain (12). Given the potential public health impact, it is vital to robustly investigate the link between maternal diet during pregnancy and childhood neurodevelopmental disorders, particularly those involving Western diets characterised by high consumption of processed meats, sugars, refined grains, and low intakes of fruits and vegetables. These diets, which are prevalent in modern societies, starkly contrast with historical human diets and may influence developmental outcomes (13). Existing literature lacks objective measurements of dietary patterns in pregnancy, and adjustment for confounding dietary patterns in childhood, when assessing this relationship.

The placenta transfers nutrients from the mother to the developing foetus during pregnancy (14). These nutrients, which include the essential n-3 long chain polyunsaturated fatty acids (n3-LCPUFA) and micronutrients such as iron, choline, iodine, zinc, and vitamins B, D, and E, are necessary for foetal brain development and function (12,15), and are obtained as part of a healthy dietary pattern. While the precise mechanisms underlying the influence of maternal diet on offspring neurodevelopment remain to be fully elucidated, various factors may be implicated in developmental processes. Among these factors are the potential impacts of dietary compounds (16) and lipid profiles (17). For example, certain dietary-derived metabolites may interact with developmental pathways in the foetus, potentially

affecting neurodevelopmental outcomes (18). Additionally, higher maternal intakes of n3-LCPUFAs,

such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are associated with

better overall diet quality (19), are reported to be neuroprotective (20).

Genetics contribute significantly to neurodevelopmental disorders, with heritability estimates as high as

80% (21). The increasing prevalence of these disorders (22) highlight the need for a better

understanding of how environmental factors interact with genetic risk (23). In this context, pregnancy

dietary influences may be moderated by the child's underlying genetic risk for neurodevelopmental

disorders, which can be succinctly captured in a polygenic risk score (PRS) (24). While twin studies

consider gene-environment interactions when estimating heritability, clinical evidence validating this

potential interaction is notably lacking (25).

In this study, we hypothesise that a Western dietary pattern in pregnancy is associated with adverse

neurodevelopmental outcomes. We sought to bridge the research gap by leveraging the thorough

neurodevelopmental clinical examinations within the Copenhagen Prospective Studies on Asthma in

Childhood 2010 (COPSAC2010) mother-child cohort. We employ external validation approaches in

three independent mother-child cohorts. Drawing from twelve metabolome datasets from three mother-

child cohorts, we juxtapose maternal and child blood profiles to shed light on the temporality of dietary

associations and their potential impact on neurodevelopment and delve into which metabolites may be

driving dietary associations on neurodevelopment.

RESULTS

Cohort Characteristics

During the 10-year clinical visit, a total of 593 children (84.7%) participating in the COpenhagen Prospective Study on Neuro-PSYCHiatric Development study (COPSYCH) underwent clinical examination for neurodevelopmental and other psychiatric disorders. Additionally, 11 children who did not complete the clinical examination, had information regarding their neurodevelopmental symptom loads. There were no significant differences in baseline sociodemographic characteristics between participants and non-participants at the 10-year visit (*Table S1*), nor between male and female children (*Table S2*).

We included 508 children with both pregnancy dietary and clinical data in our analysis, 77 (15.2%, 71% male) had any neurodevelopmental disorder. Specifically, 55 (10.8%, 76% male) were diagnosed with ADHD (25 ADHD predominantly inattentive presentation and 30 ADHD combined presentation) and 13 (2.6%, 69% male) with autism.

Identification of Dietary Patterns

We used principal component analysis (PCA) on 95 nutrient constituents (*Table S3)* from pregnancy food frequency questionnaires (FFQ) assessed at 24 weeks gestation to identify maternal dietary patterns in the COPSAC2010 cohort (*Figure S1*). Principal component 1 (PC1), which explained 44.3% of the variance, had a positive association across all food groups and represents a "Varied dietary pattern". PC2, which explained 10.7% of the variance, had positive associations with intakes of animal fats, refined grains and high-energy drinks, and negative associations with intakes of fruit, fish, and vegetables, representing a "Western dietary pattern" (*Figure 1*). Regarding macronutrient intake, PC2 (Western dietary pattern) predominantly reflected a higher intake of fats (*Figure S2A*), specifically saturated fatty acids (*Figure S2B)*. Using the maternal PC model, we predicted a child's Western dietary pattern at 10-years, allowing for a consistent comparison of dietary habits (r=0.22). A Western dietary pattern during pregnancy was negatively associated with social circumstances and positively associated with maternal pre-pregnancy body mass index (BMI), smoking during pregnancy, antibiotic use during pregnancy and a Western dietary pattern in children at 10-years of age (*Table 1*).

A Western Dietary Pattern during Pregnancy is Associated with Neurodevelopmental Disorders and Symptom Loads in Children

A Western dietary pattern during pregnancy (PC2, per SD change) was significantly associated with any neurodevelopmental disorder (OR 1.53 [1.17-2.00], p=0.002), ADHD (OR 1.66 [1.21-2.27], p=0.002), and autism (OR 2.22 [1.33-3.74], p=0.002) (*Table 2*) in multivariate modelling adjusted for pre-pregnancy maternal BMI, social circumstances, child sex, birth weight, gestational age, pregnancy smoking/antibiotic use, pre-eclampsia and a child Western dietary pattern. It was also significantly associated with symptom loads for ADHD (1.73 [0.98-2.49], p<0.001) and autism (3.21 [1.69-4.74], p<0.001), with consistent associations observed in an earlier assessment of ADHD symptom load at 8 years (1.90 [0.42-4.55], p<0.001). Moreover, ADHD symptoms at 6 years, assessed using the hyperactivity/inattention scale from the Strengths and Difficulties Questionnaire (SDQ), were also significant (0.50 [0.29-0.70], p<0.001). To illustrate the associations between the Western dietary pattern during pregnancy, neurodevelopmental outcomes, and model covariates, we employed Gaussian graphical models (*Figure 2*).

Our findings remained significant after further adjustment for maternal genetic risk for ADHD, total maternal energy intake, genomic principal components, intake of prenatal supplements (*Table S4*), and two prenatal nutrition supplementation randomised controlled trials (n3-LCPUFA and high-dose D vitamin) (*Table S5*). Associations of the pregnancy Western dietary pattern were significant for both male (1.42 [1.02-1.99], p=0.039) and female children (1.86 [1.15-3.07], p=0.012) for any neurodevelopmental disorder diagnosis (*Table S6*). Neurodevelopmental outcomes showed no significant differences related to child sex (p-interaction>0.12). Associations were comparable for both ADHD-predominantly inattentive presentation (OR 1.71 [1.13-2.56], p=0.009) and ADHD-combined presentation (OR 1.51 [1.03-2.20], p=0.033). In a subanalysis in children without a neurodevelopmental disorder diagnosis (n=428), the pregnancy Western dietary pattern association with ADHD symptom load remained significant (0.63 [0.01-1.25], p=0.048) (*Table S7*).

Validating our findings for ADHD in the Danish National Birth Cohort

We sought replication of our findings in the Danish National Birth Cohort (DNBC), which had an identical FFQ assessment undertaken at a comparable gestational age, neurodevelopmental diagnoses derived

from national registries, and ADHD symptoms from the hyperactivity/inattention scale of the SDQ

questionnaire. In our replication analysis including 59,725 mother-child pairs, we observed prevalences

of 6.8% for any neurodevelopmental disorder, 4.6% for ADHD diagnosis, and 2.7% for autism diagnosis.

We found that the association of the Western dietary pattern in pregnancy, trained in the COPSAC2010

cohort, was significantly associated with ADHD diagnosis (OR 1.07 [1.02-1.11], p=0.002), but not for

any neurodevelopmental disorder diagnosis (OR 1.03 [1.00-1.07], p=0.087) or autism diagnosis (OR

1.04 [0.98-1.09], p=0.351), in multivariable analysis (*Table S8*). Reinforcing our method, we observed

PC2 trained within the DNBC cohort was also significantly associated with ADHD diagnosis (OR 1.05

[1.01-1.10], p=0.018), with a strong correlation between PC2 trained in COPSAC2010 and the DNBC

(r=0.91). Moreover, ADHD symptoms at 7 years, assessed in a subset of 37,608 children, were also

significantly associated with the Western dietary pattern in pregnancy, trained in COPSAC2010 (0.11

[0.09-0.13] p<0.001), and within the DNBC (0.11 [0.09-0.13] p<0.001), in multivariable analysis.

A Blood Metabolomics-Derived Pregnancy Western Dietary Pattern Score Is Associated with

Neurodevelopmental Disorders in COPSAC2010

We used the blood metabolome from week 24 gestation to objectively measure the pregnancy Western

dietary pattern and validate our self-reported FFQ findings. 43.0% of 760 metabolites were significantly

associated with the pregnancy Western dietary pattern, with 34.5% surviving false discovery rate

(q<0.05). In blood metabolome modelling of the pregnancy Western dietary pattern, 43 metabolites

emerged as biomarkers (RMSECV=0.87, R^2CV=0.24). Loadings for these metabolites can be seen in

Figure 3 and *Table S9*.

A Western dietary pattern-metabolite score (WDP-MS) was derived from this model and was associated

(per SD change) with any neurodevelopmental disorder diagnosis (OR 1.42 [1.07-1.90], p=0.017), and

ADHD diagnosis (OR 1.39 [1.00-1.95], p<0.05), but not significantly with autism diagnosis (OR 1.09

[0.59-2.00], p=0.781).

To discern whether any of the 43 metabolites acted as biomarkers, or genuine mediators in the

association between the Western dietary pattern and neurodevelopmental disorders, we deployed a

backward elimination strategy. Our multivariable mediation analysis, found that 15 metabolites (*Figure

3, Table S9*) mediated the association between the Western dietary pattern and any

neurodevelopmental disorder diagnosis. The Western dietary pattern had a total effect of 5.5% on any

neurodevelopmental disorder diagnosis, of which 80.3% (p=0.003) was mediated through the selected

15 metabolites. It became evident that a predominant portion of the metabolites acting as mediators

were derived from dietary components and lipids. Prominently, plant-based metabolites such as

ergothioneine, carotene diol, and tartrate indicate potential protective effects. Conversely, many lipid-

associated metabolites, such as medium chain fatty acids like caprate and caprylate, predominantly

exhibited positive loadings, underscoring their possible detrimental impact on neurodevelopment.

We explored potential time-dependent associations by predicting an additional four WDP-MS using

comparable blood metabolome datasets in mothers (one week postpartum) and children (6 months, 18

months, and 6 years). In a sensitivity analysis, which compared the five WDP-MS without including

other covariates, significant associations were observed solely with the 24 week gestational WDP-MS

for any neurodevelopmental disorder diagnosis (OR 1.50 [1.07-2.11], p=0.020), ADHD diagnosis (OR

1.58 [1.08-2.33], p=0.020) and directionally for autism diagnosis (OR 1.74 [0.84-3.57], p=0.131). This

was the case despite the strong correlations noted between maternal dietary metabolite scores (r=0.68,

Table S10). Findings were consistent for ADHD (1.43 [0.41-2.45], p=0.006) and autism symptom loads

(2.86 [0.84-4.89], p=0.006). We substantiated these temporal associations by employing linear mixed

models. Through this approach, we discerned that the initial magnitude of the Western dietary pattern

during pregnancy, reflected by the model's intercept, likewise served as a predictor for any

neurodevelopmental disorder (OR 1.56 [1.24-1.97], p<0.001), ADHD diagnosis (OR 1.63 [1.25-2.12],

p<0.001) but not autism diagnosis (OR 1.34 [0.813-2.18], p=0.242). Additionally, there were likewise

significant associations with ADHD (1.69 [0.99-2.40], p<0.001) and autism symptom loads (3.65 [2.24-

5.06], p<0.001).

Western Dietary Pattern-Metabolite Score Predicts ADHD Diagnosis in the VDAART Mother-

Child Cohort

As our blood metabolome modelling of the Western dietary pattern during pregnancy was associated

with ADHD diagnosis and symptom load in COPSAC2010, we sought replication of our findings in the

Vitamin D Antenatal Asthma Reduction Trial cohort (VDAART), a large US-based mother-child cohort.

We included participants with corresponding pregnancy blood metabolome and ADHD outcome data

(*n=656*). Among the children in the VDAART cohort, caregivers reported a diagnosis for ADHD or

attention deficit disorder for 18 children (2.7%) by age 6 years and 57 children (8.7%) by age 8 years.

Significant cohort characteristic differences were observed between the COPSAC2010 and VDAART

cohorts (*Table S11*), encompassing age, income, maternal education, maternal age, gestational age,

maternal smoking, race, maternal pre-pregnancy BMI, birthweight, and caesarean section delivery

(p<0.001). Supplementary Figures 3 shows the metabolomic variability in the COPSAC2010 and

VDAART, illustrating closely matched variances across pregnancy samples.

In the VDAART cohort, which includes blood metabolome profiling at two pregnancy timepoints during

early (10-18 week) and late gestation (32-38 weeks), we used COPSAC2010 cohort-trained models to

predict two WDP-MS to assess their association with ADHD diagnosis. The metabolite scores at both

time points were positively associated with intakes of deep-fried foods, processed meats and margarine,

and negatively associated with intakes of various vegetables, whole grain foods and fruit in the VDAART

cohort, as assessed by independent food frequency questionnaires (*Figure S4*). There was a strong

correlation between the VDAART FFQ's principal component 1 and the predicted WDP-MS during early

(r=0.48, p=1.4×10^{-46}) and late (r=0.46, p=2.3×10^{-42}) pregnancy, underscoring the WDP-MS validity in

predicting dietary patterns across diverse populations.

Despite significant differences in cohort characteristics, our blood metabolomics analysis successfully

replicated the univariate association between the WDP-MS and ADHD diagnosis at age 6 in both early

(OR 2.64 [1.56-4.64], p<0.001) and late pregnancy (OR 1.85 [1.12-3.16], p=0.020), in the VDAART

cohort. After adjusting for similar covariates to those used in the COPSAC2010 cohort, a significant

association remained between the WDP-MS and ADHD diagnosis in early pregnancy (OR 2.33 [1.26-

4.42], p=0.008) but not in late pregnancy (OR 1.67 [0.90-3.20], p=0.113). For further robustness of our

findings, we assessed children ever having had a ADHD diagnosis up to age 8. The WDP-MS

successfully univariately replicated, albeit with attenuated estimates in early (OR 1.71 [1.28-2.32],

p<0.001) and late pregnancy (OR 1.37 [1.04-1.83], p=0.030). Associations remained significant after

multivariable adjustment in early pregnancy (OR 1.45 [1.02-2.06], p=0.039) but not late pregnancy (OR

1.11 [0.79-1.58], p=0.544).

In sensitivity analysis, we independently employed the backward elimination strategy, previously

outlined for the COPSAC2010 cohort, on the metabolites overlapping with the VDAART 10-18 weeks

and 32-38 weeks time points. In doing so, we identified the mediating metabolites in the association

between the Western dietary pattern in COPSAC2010 to ADHD diagnosis (*Figure S5*). Leveraging

COPSAC2010's mediating metabolites, we performed a sensitivity analysis to contrast the performance

of a WDP-MS using only these potentially causally mediating metabolites against the WDP-MS with all

metabolites, for predicting ADHD in the VDAART cohort. At the 10-18 week timepoint, in a multivariable

model, the subset of mediating metabolites improved ADHD diagnosis prediction at 6 years (OR 2.85

[1.60-5.20], p<0.001), significantly moreso (nested model chi-squared test p=0.012) than our model

with all 18 metabolites. However, at the 32-38 week timepoint the subset of mediating metabolites (OR

1.81 [0.95-3.58], p=0.078) did not perform significantly better than the WDP-MS with all 19 metabolites

(nested model chi-squared test p=0.423). To replicate the potential time-dependent association of the

Western dietary pattern, we predicted three additional WDP-MS for children in VDAART (1 year, 3

years, and 6 years). When incorporating the three child WDP-MS in a model with the two pregnancy

WDP-MS timepoints, we observed significant associations only with the early pregnancy WDP-MS for

ADHD diagnosis at age 6 (OR 1.97 [1.01-3.80], p = 0.044) and ADHD diagnosis up to age 8 (OR 1.65

[1.11-2.45], p=0.013).

Western Dietary Pattern-Metabolite Score Predicts ADHD Symptoms in COPSAC2000

We sought further replication in the COPSAC2000 mother-child cohort, where we included 328

participants with both neonatal dried blood spots (DBS) metabolic profiling and ADHD symptom load

from the Adult ADHD Self-Report Scale (ASRS) at age 18. We developed a Western dietary pattern dry

blood spot (WDP-DBS) score using overlapping DBS metabolites from the COPSAC2010 cohort to

predict the association with ADHD symptom load. Supplementary Figure 6 illustrates the metabolomic

variability between the COPSAC2010 and COPSAC2000 newborn samples, demonstrating

comparable variance across cohorts.

To substantiate the WDP-DBS score's relevance, we first confirmed its significance within the

COPSAC2010 cohort, showing a strong association with ADHD symptom load, in multivariable

modelling (1.19 [0.41-1.98], p=0.003), before applying it to COPSAC2000 data. In COPSAC2000, we

successfully replicated this association between the WDP-DBS and ADHD symptom load (0.44 [0.01-

0.86], p=0.045), but this finding didn't survive covariate adjustment (0.34 [-0.08-0.77], p=0.114). In

sensitivity analysis, we enhanced cross-correlations between COPSAC2010 and COPSAC2000

cohorts from >0.4 to >0.6, and restricted the analysis to 626 metabolites with similar distributions

between cohorts (Kolmogorov-Smirnov p ≥ 0.05). This approach led to more pronounced univariate

(0.49 [0.06-0.91], p=0.027) and multivariable associations (0.41 [-0.02-0.83], p=0.062).

Moderating Effects of Genetics, Maternal BMI, and Child Sex on Diet-Neurodevelopment

Associations

In a subanalysis, we investigated if established risk factors (child genetic risk (ADHD and autism PRS),

maternal pre-pregnancy BMI, and child sex) moderate the association of the Western dietary pattern

during pregnancy with neurodevelopmental outcomes in COPSAC2010. Supplementary Table 12

provides more details on the independent associations of these factors on neurodevelopmental

outcomes.

ADHD (11.8%) and autism (2.7%) diagnosis, had limited variability in our dataset, prompting us to

assess the association of the Western dietary pattern using strata of median split maternal pre-

pregnancy BMI (above and below 23.7) and PRS scores (*Figure 4A/B*). In multivariable analyses,

children born to mothers with a higher BMI and with a greater genetic predisposition for the respective

disorder showed the strongest associations with the Western dietary pattern. For ADHD diagnosis, this

group had an odds ratio of 2.18 [1.30-3.74], p=0.004, and for autism diagnosis, it was 4.59 [2.33-9.78],

$p<10^{-4}$. When further stratified by child sex, findings continued to show consistent significance across

both sexes (*Figure S7A/B*). Findings were again consistent when considering the objectively measured

WDP-MS (*Figure S8A/B*).

To assess the association of the Western dietary pattern on ADHD and autism symptom loads, we

employed a tertile split. Concordantly, we found that both ADHD and autism consistently showed that

the association of the Western dietary pattern was most pronounced in children born to mothers in the

highest pre-pregnancy BMI group (>25.4) and in children with the highest genetic risk for the respective

disorders (*Figure 4C/D*). For ADHD symptom load, this group had an estimate of 5.07 [3.12-7.03],

$p<10^{-6}$, and for autism symptom load it was 13.5 [9.51-17.5], $p<10^{-10}$. When further stratified by child

sex, this pronounced association persisted significantly only for male children (ADHD: 8.24 [5.19-11.3],

$p<10^{-6}$, autism: 24.6 [19.0-30.2], $p<10^{-4}$ (*Figure S7C/D*). Findings were again consistent when

considering the objectively measured WDP-MS (*Figure S8A/B*). A further graphic is provided (*Figure*

S9) for ADHD (*A-C*) and autism symptom loads (D-F) showing model estimates when considering

maternal pre-pregnancy BMI across the categories <25, 25-30, and >30.

DISCUSSION

In our large prospective general population COPSAC2010 mother-child cohort, we observed strong associations between a Western dietary pattern during pregnancy with ADHD and autism diagnoses, as well as related symptom loads for these disorders in 10-year-old children. Our findings for ADHD were corroborated in three additional cohorts, which together encompass more than 60,000 mother-child pairs. From the 43 metabolites associated with a Western dietary pattern, a subset of 15 mediating metabolites notably strengthened the association with ADHD diagnosis in external validation. In the COPSAC2010 and VDAART cohorts, we consistently found dietary metabolite score associations in early-mid pregnancy had the strongest associations with neurodevelopmental outcomes, suggesting that this may be a particularly sensitive period of neurodevelopment to dietary influences. Finally, we observed that the association of the Western dietary pattern during pregnancy with ADHD and autism diagnoses, as well as symptom loads, was markedly stronger in children with higher genetic predisposition and maternal pre-pregnancy BMI, particularly in male children.

Expanding on prior research, our study, reinforced by clinically assessed outcomes, presents compelling evidence indicating a potential association between maternal dietary habits during pregnancy and child neurodevelopment. The persistence of the Western dietary pattern's association on ADHD symptoms, even in children without a neurodevelopmental disorder diagnosis, suggests that the pregnancy Western dietary pattern may also affect the subclinical population. A Norwegian study of 77,768 mother-child pairs found that higher maternal adherence to dietary guidelines was inversely correlated with ADHD diagnosis and symptom severity, while ultra-processed food was positively associated with ADHD symptom severity (26). This study revealed no link between the diet of 3-year-olds and ADHD outcomes, aligning with our results. Conversely, the Raine Study associated a Western dietary pattern in 1,799 adolescents with ADHD but did not explore maternal dietary influences (27). In a cross-cohort study of 800 pregnant women in the US, weak associations were found between established reference dietary patterns and autism-related traits and diagnosis (28). Our study adds to this existing literature by identifying potential temporal associations of a Western dietary pattern on child neurodevelopmental outcomes, using both maternal and child self-reported dietary intakes, and the objective blood metabolome (29).

Our findings suggest a potential interplay between the prenatal environment and child genetics that

may influence child neurodevelopment. Males with high genetic risk born from mothers with high pre-

pregnancy BMI had the strongest associations with the pregnancy Western dietary pattern. Twin studies

support the hypothesis that such interactions play a significant role in the development of these

disorders (30,31). Whilst heritability for ADHD and autism is high, with genetic influences accounting

for approximately 70-80% of the phenotypic variance (32), current estimates for heritability encompass

gene-environment interaction effects (33). Our findings highlight the potential significant role of the

environment in the aetiology of ADHD and autism. It is worth noting that much of the heritability for

ADHD and autism is explained by SNPs in regulatory regions rather than coding regions (34), providing

further evidence for the role of the environment in these disorders. This may aid researchers in

understanding the underlying mechanisms contributing to the development of these disorders.

The main strength of our study is the prospectively assessed COPSAC2010 cohort followed from

pregnancy through childhood, with a deep psychiatric and dimensional psychopathological

characterization provided by the COPSYCH project. We use pregnancy and early-life samples taken

before onset of disease and symptoms, which allows for the identification of potential risk factors and

the directionality of associations. The breadth of data from the COPSAC2010 cohort enabled the

inclusion of relevant covariates, and the depth of phenotyping allowed for genetic characterisation,

making assessments of gene-environment interactions possible. By utilising a validated

semiquantitative food frequency questionnaire and identifying dietary patterns via data-driven

approaches, our findings more accurately reflect the dietary patterns that are existing in the population

(35). We validate this methodology by identifying a highly correlated dietary pattern within the DNBC.

Although our analysis lacked information on morning sickness and hyperemesis gravidarum, our FFQ

was registered at 24 weeks gestation with 1 month recall, outside the period when these symptoms are

commonly experienced. Furthermore, universal accessibility of a uniform prenatal care in Denmark

enhances the reliability of our findings. The pregnancy Western dietary pattern was derived from

estimates of nutrient constituents, this approach is not novel (36), and is supported by a recent meta-

analysis across 123 studies (37), which reported the reliably of FFQs to capture nutrient constituents

with correlation coefficients consistently exceeding 0.5 for most nutrients. This nutrient-centric

methodology may offer accurate representation of dietary patterns across diverse populations, since

nutrients align more closely with biological and physiological processes than food group categories.

Acknowledging the limitations of FFQs, including recall bias and quantification challenges, our study

incorporates blood metabolomics to provide objective biomarkers for dietary intake. This approach,

while not without its own limitations, such as the transient nature of dietary-derived biomarkers, has

validated the Western dietary pattern both internally, through a strong metabolomic imprint, and

externally, in two independent FFQs in the VDAART cohort. Many studies have likewise found strong

dietary signatures in the metabolome, suggesting this may be a promising avenue for personalised

nutrition and targeted therapeutic strategies (29).

Our findings for ADHD were strengthened by external validation in three independent mother-child

cohorts. This validation enhances the reliability and generalisability of our results, despite the presence

of notable differences in cohort characteristics. The validation for ADHD diagnosis in the large-scale

DNBC cohort, encompassing 59,725 mother-child pairs, underscores the significant relevance and

utility of our findings in the general population. Moreover, validation from the US-based VDAART cohort

demonstrates the broad applicability of our findings across diverse ethnic and racial groups, dietary

habits, and socio-economic spectra. In VDAART, our external validation was significantly strengthened

by focusing on a subset of metabolites identified in causal mediation analysis, implying these

metabolites may be crucial intermediaries in the associations observed. Additionally, the VDAART

findings enhance our understanding from COPSAC2010, with stronger associations of the Western

dietary pattern for ADHD in early pregnancy (10-18 weeks), which may reflect a more sensitive period

of neurodevelopment. Given this context, it may not be surprising to see weaker associations from

neonatal DBS in COPSAC2000, potentially reflecting dietary intakes in late pregnancy.

We cannot rule out potential confounding by maternal phenotypic factors that relate to child

neurodevelopmental disorders, however supplemental analysis adjusting for maternal genetic risk did

not change our main findings. Given the observational nature of our data, we cannot elucidate the

critical window of these dietary associations. Moreover, it is possible that there are discrepancies in the

metabolomics platforms concerning metabolite detection, annotations, and cross-platform compatibility,

which may introduce bias. Nevertheless, the same metabolomics platform was employed for all

maternal and child timepoints in the COPSAC2010 and VDAART cohorts (HD4, Metabolon, Inc.), as

well as for the DBS metabolomics profiles in both the COPSAC2010 and COPSAC2000 cohorts (38).

A further limitation is that metabolite scores for children, derived from modelling on pregnant mothers,

may not reflect dietary patterns in childhood. However, correlations between pregnancy and child

metabolite scores were consistently ≥ 0.33 in both COPSAC2010 and VDAART. Whilst dietary intakes

remain stable across pregnancy trimesters (39), our ability to distinguish potential acute effects of a

pregnancy Western dietary pattern or longer-term effects is limited by our reliance on a single FFQ

assessment.

Moving forward, future research should focus on establishing causality to further elucidate the

relationship between Western dietary patterns in pregnancy and neurodevelopmental outcomes. While

animal studies have provided valuable insights (40), further clinical investigations are warranted. Our

findings underscore the potential for targeted prevention strategies, and conducting randomised

controlled trials would be instrumental in establishing causality. Additionally, genetic studies could

strengthen causal inference in our observational data (41).

In conclusion, a Western dietary pattern in pregnancy was strongly associated with ADHD and autism,

and with symptom loads for these disorders. Our findings suggest that early to mid-pregnancy may be

a particularly sensitive window during which dietary influences may impact child neurodevelopment.

Highlighting specific subgroup effects, our research points towards the potential for tailored dietary

guidelines during pregnancy, especially for at-risk populations. Ultimately, our research underscores

the importance of developing targeted dietary interventions for pregnant women to potentially mitigate

the risk of neurodevelopmental disorders in children.

Acknowledgements

We express our deepest gratitude to the children and families of the COPSAC2010, COPSAC2000 and

VDAART cohorts for all their support and commitment. We acknowledge and appreciate the unique

efforts of the COPSAC research team. We acknowledge all funding received by COPSAC, listed on

www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694 and R269-2017-5); The Ministry of

Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B) and The

Capital Region Research Foundation have provided core support to the COPSAC research centre. This

project has received funding from the European Research Council (ERC) under the European Union's

Horizon 2020 research and innovation programme (grant agreement No. 946228) (BC). MAR is funded

by the Novo Nordisk Foundation (Grant no NNF21OC0068517). CP was supported by an Australian

National Health and Medical Research Council (NHMRC) L3 Investigator Grant (1196508) and by a

grant from the Lundbeck Foundation (ID: R246-2016-3237). JL-S (R01HL123915, R01HL155742, and

R01HL141826) and SHC (K01HL153941) are funded through the National Institute of Heart, Lung, and

Blood Institute.

The Danish National Birth Cohort was established with a significant grant from the Danish National

Research Foundation. Additional support was obtained from the Danish Regional Committees, the

Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the

Health Foundation and other minor grants. The DNBC Biobank has been supported by the Novo

Nordisk Foundation and the Lundbeck Foundation. Follow-up of mothers and children have been

supported by the Danish Medical Research Council (SSVF 0646, 271-08-0839/06-066023, O602-

01042B, 0602-02738B), the Lundbeck Foundation (195/04, R100-A9193), The Innovation Fund

Denmark 0603-00294B (09-067124), the Nordea Foundation (02-2013-2014), Aarhus Ideas (AU R9-

A959-13-S804), University of Copenhagen Strategic Grant (IFSV 2012), and the Danish Council for

Independent Research (DFF – 4183-00594 and DFF - 4183-00152).

Authors Contributions:

DH has written the first draft of the manuscript. All co-authors have provided important intellectual input and contributed considerably to the analyses and interpretation of the data. All authors guarantee that the accuracy and integrity of any part of the work have been appropriately investigated and resolved and all have approved the final version of the manuscript. The corresponding author had full access to the data, with the exception of the DNBC cohort, where analysis was run by TH. The corresponding author had final responsibility for the decision to submit for publication.

Competing Interests Statement:

BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. BYG has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 – December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administered by them. She has no other conflicts to disclose. JL-S is a scientific advisor for Precion Inc and a consultant to Tru Diagnostic, Inc.

Remaining authors declare no potential, perceived, or real conflict of interest regarding the content of this manuscript. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the study.

References (Main Text)

1.   Bougeard C, Picarel-Blanchot F, Schmid R, Campbell R, Buitelaar J. Prevalence of Autism
Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature
Review. Front Psychiatry. 2021 Oct 27;12:744709.

2.   Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, et al.
Incidence Rates and Cumulative Incidences of the Full Spectrum of Diagnosed Mental Disorders
in Childhood and Adolescence. JAMA Psychiatry. 2020 Feb 1;77(2):155–64.

3.   Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic
review. Neurotherapeutics. 2012 Jul;9(3):490–9.

4.   Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al.
The global prevalence of autism spectrum disorder: A three-level meta-analysis. Front Psychiatry.
2023 Feb 9;14:1071181.

5.   Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P. Childhood attention-deficit
hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500
twin pairs. J Child Psychol Psychiatry. 2012 Jan;53(1):73–80.

6.   Makransky G, Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating
Scale (ADHD-RS): measurement invariance across gender, age, and informant. Assessment.
2014 Dec;21(6):694–705.

7.   Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a
brief quantitative measure of autistic traits: comparison of the social responsiveness scale with
the autism diagnostic interview-revised. J Autism Dev Disord. 2003 Aug;33(4):427–33.

8.   Cortés-Albornoz MC, García-Guáqueta DP, Velez-van-Meerbeke A, Talero-Gutiérrez C. Maternal
Nutrition and Neurodevelopment: A Scoping Review. Nutrients [Internet]. 2021 Oct 8;13(10).
Available from: http://dx.doi.org/10.3390/nu13103530

9.   Fernandes DJ, Spring S, Roy AR, Qiu LR, Yee Y, Nieman BJ, et al. Exposure to maternal high-
fat diet induces extensive changes in the brain of adult offspring. Transl Psychiatry. 2021 Mar
2;11(1):149.

10.   Giriko CÁ, Andreoli CA, Mennitti LV, Hosoume LF, Souto TDS, Silva AV da, et al. Delayed
physical and neurobehavioral development and increased aggressive and depression-like
behaviors in the rat offspring of dams fed a high-fat diet. Int J Dev Neurosci. 2013
Dec;31(8):731–9.

11.   Mitchell AJ, Khambadkone SG, Dunn G, Bagley J, Tamashiro KLK, Fair D, et al. Maternal
Western-style diet reduces social engagement and increases idiosyncratic behavior in Japanese
macaque offspring. Brain Behav Immun [Internet]. 2022 Jul 6; Available from:
http://dx.doi.org/10.1016/j.bbi.2022.07.004

12.   Prado E, Dewey K. Nutrition and Brain Development in Early Life [Internet]. Prenatal and
Childhood Nutrition. 2015. p. 79–126. Available from: http://dx.doi.org/10.1201/b18040-6

13.   Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, et al. Origins and
evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005
Feb;81(2):341–54.

14.   Devarshi PP, Grant RW, Ikonte CJ, Hazels Mitmesser S. Maternal Omega-3 Nutrition, Placental
Transfer and Fetal Brain Development in Gestational Diabetes and Preeclampsia. Nutrients
[Internet]. 2019 May 18;11(5). Available from: http://dx.doi.org/10.3390/nu11051107

15.   Taylor MR, Chuang C, Carrasco KD, Nagatomo S, Rucklidge JJ. Dietary and Micronutrient
Treatments for Children with Neurodevelopment Disorders [Internet]. Vol. 5, Current
Developmental Disorders Reports. 2018. p. 243–52. Available from:

http://dx.doi.org/10.1007/s40474-018-0150-5

16. Halliwell B, Cheah IK, Tang RMY. Ergothioneine - a diet-derived antioxidant with therapeutic
potential. FEBS Lett. 2018 Oct;592(20):3357–66.

17. Prince N, Chu SH, Chen Y, Mendez KM, Hanson E, Green-Snyder L, et al. Phenotypically driven
subgroups of ASD display distinct metabolomic profiles. Brain Behav Immun. 2023 Jul;111:21–9.

18. Poornimai Abirami GP, Radhakrishnan RK, Johnson E, Roshan SA, Yesudhas A, Parveen S, et
al. The Regulation of Reactive Neuroblastosis, Neuroplasticity, and Nutraceuticals for Effective
Management of Autism Spectrum Disorder. Adv Neurobiol. 2020;24:207–22.

19. Naveed S, Lakka T, Haapala EA. An Overview on the Associations between Health Behaviors
and Brain Health in Children and Adolescents with Special Reference to Diet Quality [Internet].
Vol. 17, International Journal of Environmental Research and Public Health. 2020. p. 953.
Available from: http://dx.doi.org/10.3390/ijerph17030953

20. Basak S, Duttaroy AK. Maternal PUFAs, Placental Epigenetics, and Their Relevance to Fetal
Growth and Brain Development. Reprod Sci [Internet]. 2022 Jun 8; Available from:
http://dx.doi.org/10.1007/s43032-022-00989-w

21. Pettersson E, Lichtenstein P, Larsson H, Song J, Attention Deficit/Hyperactivity Disorder Working
Group of the iPSYCH-Broad-PGC Consortium, Autism Spectrum Disorder Working Group of the
iPSYCH-Broad-PGC Consortium, Bipolar Disorder Working Group of the PGC, Eating Disorder
Working Group of the PGC, Major Depressive Disorder Working Group of the PGC, Obsessive
Compulsive Disorders and Tourette Syndrome Working Group of the PGC, Schizophrenia
CLOZUK, Substance Use Disorder Working Group of the PGC, Agrawal A, et al. Genetic
influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings,
and genetic data of 333 748 cases and controls - CORRIGENDUM. Psychol Med. 2019
Jan;49(2):351.

22. Atladottir HO, Gyllenberg D, Langridge A, Sandin S, Hansen SN, Leonard H, et al. The
increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive
multinational comparison. Eur Child Adolesc Psychiatry. 2015 Feb;24(2):173–83.

23. Tran NQV, Miyake K. Neurodevelopmental Disorders and Environmental Toxicants: Epigenetics
as an Underlying Mechanism. Int J Genomics Proteomics [Internet]. 2017 [cited 2023 Jan
7];2017. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439185/

24. Keers R, Coleman JRI, Lester KJ, Roberts S, Breen G, Thastum M, et al. A Genome-Wide Test
of the Differential Susceptibility Hypothesis Reveals a Genetic Predictor of Differential Response
to Psychological Treatments for Child Anxiety Disorders. Psychother Psychosom. 2016 Apr
5;85(3):146–58.

25. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World
Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about
the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789–818.

26. Borge TC, Biele G, Papadopoulou E, Andersen LF, Jacka F, Eggesbø M, et al. The associations
between maternal and child diet quality and child ADHD - findings from a large Norwegian
pregnancy cohort study. BMC Psychiatry. 2021 Mar 8;21(1):139.

27. Howard AL, Robinson M, Smith GJ, Ambrosini GL, Piek JP, Oddy WH. ADHD is associated with
a "Western" dietary pattern in adolescents. J Atten Disord. 2011 Jul;15(5):403–11.

28. Vecchione R, Wang S, Rando J, Chavarro JE, Croen LA, Fallin MD, et al. Maternal Dietary
Patterns during Pregnancy and Child Autism-Related Traits: Results from Two US Cohorts.
Nutrients [Internet]. 2022 Jun 30;14(13). Available from: http://dx.doi.org/10.3390/nu14132729

29. Noerman S, Landberg R. Blood metabolite profiles linking dietary patterns with health-Toward
precision nutrition. J Intern Med. 2023 Apr;293(4):408–32.

30. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019
Apr;24(4):562–75.

31. Santos JX, Rasga C, Marques AR, Martiniano H, Asif M, Vilela J, et al. A Role for Gene-
Environment Interactions in Autism Spectrum Disorder Is Supported by Variants in Genes
Regulating the Effects of Exposure to Xenobiotics. Front Neurosci. 2022 May 19;16:862315.

32. Ma SL, Chen LH, Lee CC, Lai KYC, Hung SF, Tang CP, et al. Genetic Overlap Between
Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Gene. Front Neurosci.
2021 Apr 27;15:649588.

33. Bateson P, Gluckman P. Plasticity, Robustness, Development and Evolution. Cambridge
University Press; 2011. 166 p.

34. Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, et al. Partitioning heritability of
regulatory and cell-type-specific variants across 11 common diseases. Am J Hum Genet. 2014
Nov 6;95(5):535–52.

35. Newby PK, Tucker KL. Empirically derived eating patterns using factor or cluster analysis: a
review. Nutr Rev. 2004 May;62(5):177–203.

36. Zhao J, Li Z, Gao Q, Zhao H, Chen S, Huang L, et al. A review of statistical methods for dietary
pattern analysis. Nutr J. 2021 Apr 19;20(1):37.

37. Cui Q, Xia Y, Wu Q, Chang Q, Niu K, Zhao Y. A meta-analysis of the reproducibility of food
frequency questionnaires in nutritional epidemiological studies. Int J Behav Nutr Phys Act. 2021
Jan 11;18(1):12.

38. Gürdeniz G, Ernst M, Rago D, Kim M, Courraud J, Stokholm J, et al. Neonatal metabolome of
caesarean section and risk of childhood asthma. Eur Respir J [Internet]. 2022 Jun;59(6).
Available from: http://dx.doi.org/10.1183/13993003.02406-2021

39. Savard C, Lemieux S, Weisnagel S, Fontaine-Bisson B, Gagnon C, Robitaille J, et al. Trimester-
Specific Dietary Intakes in a Sample of French-Canadian Pregnant Women in Comparison with
National Nutritional Guidelines [Internet]. Vol. 10, Nutrients. 2018. p. 768. Available from:
http://dx.doi.org/10.3390/nu10060768

40. Urbonaite G, Knyzeliene A, Bunn FS, Smalskys A, Neniskyte U. The impact of maternal high-fat
diet on offspring neurodevelopment [Internet]. Vol. 16, Frontiers in Neuroscience. 2022. Available
from: http://dx.doi.org/10.3389/fnins.2022.909762

41. Pingault JB, O'Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F. Using genetic data to
strengthen causal inference in observational research. Nat Rev Genet. 2018 Sep;19(9):566–80.

582 **Figure 1.** Figure showing the pregnancy Varied and Western dietary patterns derived from nutrient

583 constituents (PC1 and PC2) and their associations with food groups. Multivariable analysis shows the

584 Western dietary pattern is highly associated with any neurodevelopmental disorder diagnosis (OR 1.53,

585 [1.17 - 2] (p = 0.002), ADHD diagnosis 1.66 [1.21 - 2.27] (p = 0.002), and autism diagnosis 2.22 [1.33 -

586 3.74] (p = 0.002), but the Varied dietary pattern is not significantly associated with neurodevelopmental

587 disorders (p>0.288). Yellow represents positive associations with PC1, while red and green denote

588 positive and negative associations with PC2, respectively.

Figure 2. Graphical models illustrate associations (partial correlations p<0.05) between the Western

dietary pattern during pregnancy, neurodevelopmental outcomes A: ADHD diagnosis, B: ADHD

Symptom Load (ADHD-RS), C: Autism diagnosis, D: Autism Symptom Load (SRS-2), and model

covariates. Models include child ADHD PRS (A&B) and autism PRS (C&D) as additional covariates.

Figure 3. The 43 metabolites, selected by the sparse partial least squares model, represent those

associated with the Western dietary pattern during pregnancy at 24 weeks gestation in COPSAC2010.

Positive metabolite scores indicate a positive association, while negative scores suggest an inverse

relationship with this dietary pattern. A systematic backward elimination pinpointed 15 metabolites as

mediators between the Western dietary pattern and any neurodevelopmental disorders. Notably,

dietary-derived compounds, like ergothioneine, suggest potential protective roles, while certain lipid-

associated metabolites hint at possible detrimental impacts on neurodevelopment.

Western Dietary Pattern Associations with Neurodevelopmental Disorders

Figure 4. Modulation of the Western Dietary Pattern on Neurodevelopmental Outcomes in

COPSAC2010 Cohort. Odds ratio estimates for ADHD (A) and autism diagnoses (B) based on

interactions of the Western dietary pattern, maternal pre-pregnancy BMI (split at median value 23.7),

and child's polygenic risk score (PRS) (median split) for ADHD and autism. Estimates for ADHD (C)

and autism (D) symptom loads based on the Western dietary pattern, considering tertiles of maternal

pre-pregnancy BMI and child's PRS for ADHD and autism. Odds ratios and estimates are in relation to

a change of 1 SD of the Western dietary pattern. Stars represent significance levels: * indicates p <

0.05, ** indicates p < 0.01, and *** indicates p < 0.001, with "NS" denoting non-significant results (p ≥

0.05). Further details, including the individual associations of these modulating factors, can be found in

Table S11.

Western Dietary Pattern (PC2) Covariate Associations	Low Western Diet	Mid Western Diet	High Western Diet	p-value
n =	170	169	169	
Male Sex (%)	77 (45.3)	98 (58.0)	91 (53.8)	0.058
Social circumstances (mean (SD))	0.34 (0.87)	0.06 (0.94)	-0.41 (1.01)	<0.001
Maternal pre-pregnancy BMI (mean(SD))	24.12 (4.18)	24.41 (3.80)	25.36 (5.06)	0.026
Smoking during pregnancy (%)	5 (2.9)	7 (4.1)	26 (15.4)	<0.001
Gestational age in (days) (mean (SD))	279.18 (12.36)	279.62 (11.43)	279.14 (10.13)	0.911
Birthweight (kg) (mean (SD))	3.55 (0.56)	3.55 (0.53)	3.58 (0.53)	0.815
Antibiotics during pregnancy (%)	49 (29.0)	53 (31.4)	73 (43.2)	0.013
Pre-eclampsia during pregnancy (%)	5 (3.0)	9 (5.3)	8 (4.7)	0.539
Child Western Dietary Pattern (mean (SD))	-0.18 (0.89)	-0.07 (1.01)	0.26 (1.08)	<0.001
n3-LCPUFA Pregnancy RCT (%)	82 (48.2)	88 (52.1)	88 (52.1)	0.717
High dose Vitamin D Pregnancy RCT (%)	70 (51.1)	66 (47.1)	64 (45.4)	0.622
Total energy consumption (FFQ) (mean (SD))	9131 (1982)	8497 (1968)	9502 (2545)	<0.001
Maternal ADHD PRS (mean (SD))	-0.12 (1.00)	-0.05 (0.97)	0.09 (1.04)	0.208
Child ADHD PRS (mean (SD))	-0.17 (1.06)	-0.03 (1.00)	0.11 (0.99)	0.060
Child Autism PRS (mean (SD))	-0.01 (1.02)	-0.05 (1.05)	-0.01 (1.04)	0.921

615   **Table 1.** Model covariates stratified by low, middle and high (tertiles) for the pregnancy Western dietary

616   pattern, in children who were clinically assessed for neurodevelopmental disorders.

617   **Footnote:**

618   † PC2: Principal Component 2, BMI: Body Mass Index, RCT: Randomised Controlled Trial, FFQ: Food Frequency Questionnaire,

619   PRS: Polygenic Risk Score.

	Univariate Model	Multivariable Model
Neurodevelopmental Diagnosis	**Odds Ratio [95% CI] p-value**	**Odds Ratio [95% CI] p-value**
Any Neurodevelopmental Disorder Diagnosis	1.66 [1.31 - 2.11] (p < 0.001)	1.53 [1.17 - 2.00] (p = 0.002)
ADHD Diagnosis	1.84 [1.42 - 2.41] (p < 0.001)	1.66 [1.21 - 2.27] (p = 0.002)
Autism Diagnosis	2.38 [1.50 - 3.79] (p < 0.001)	2.22 [1.33 - 3.74] (p = 0.002)
Neurodevelopmental Symptom Loads	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**
ADHD Symptom Load (ADHD-RS)	2.26 [1.53 - 2.98] (p < 0.001)	1.73 [0.98 - 2.49] (p < 0.001)
Autism Symptom Load (SRS-2)	4.37 [2.92 - 5.81] (p < 0.001)	3.21 [1.69 - 4.74] (p < 0.001)

Table 2. Regression analysis of the Western dietary pattern during pregnancy and neurodevelopmental

outcomes. Odds ratios and estimates are interpreted as the association of 1 standard deviation of the

pregnancy Western dietary pattern. **Model A**: Univariate analysis. **Model B**: Multivariable analysis

(multivariable model adjusted for pre-pregnancy maternal BMI, social circumstances (household

income, maternal education level, and maternal age), child sex, birth weight, gestational age, pregnancy

smoking/antibiotic use, pre-eclampsia and a child Western dietary pattern at 10-years of age).

METHODS

Study Design

The primary analysis of our research was conducted within the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC2010) mother-child cohort, supplemented by validation analyses in three independent mother-child cohorts: the Danish National Birth Cohort (DNBC), the Vitamin D Antenatal Asthma Reduction Trial (VDAART), and COPSAC2000. The COPSAC2010 cohort includes 700 mother-child pairs with extensive phenotyping from 14 clinical visits and exposure assessments since birth, including infants born within a gestational range of 30 to 42 weeks, thus covering both preterm and full-term births (42). Outcome data for this study was derived from the COpenhagen Prospective Study on Neuro-PSYCHiatric Development (COPSYCH) study (43)nested within the COPSAC2010 mother-child cohort, at age 10 years.

In validation analysis, we utilised the DNBC, a large mother-child cohort that recruited over 100,000 pregnant mothers from early gestation, approximately 35% of pregnancies during the recruitment period, to validate our findings of the food frequency questionnaire derived dietary pattern (44,45). Furthermore, we used the large independent US-based VDAART mother-child cohort (NCT00920621) (*n=656*) (46), to validate our blood metabolome modelling (47), and further validated our findings in the COPSAC2000 cohort (n=348), using metabolic profiles from neonatal dried blood spots (DBS) (48).

The COPSYCH 10-year visit

The COPSYCH study comprised a 2-day clinical visit that focused on neurodevelopment, reflected by neurocognition and psychopathology (43). Clinical examinations were carried out between January 2019 and December 2021.

We used both the International Classification of Disorders 10th Revision (ICD-10) of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for research diagnoses based on clinical information from the 10-year visit. ADHD ICD-10 diagnostic codes assigned at the COPSYCH visit included: DF90.0 (*Disturbance of activity and attention*), DF90.8 (*Other hyperkinetic disorders*) and DF98.8C (*Attention deficit disorder without hyperactivity*). For secondary analysis, we further specified

ADHD combined presentation (DSM-5) (fulfilling ICD-10 DF90.0 or DF90.8) and *ADHD predominantly*

inattentive presentation (DSM-5) (fulfilling ICD-10 DF98.8*C*). Autism ICD-10 diagnostic codes assigned

were: DF84.0 (*Childhood autism*), DF84.5 (*Asperger's syndrome*) and DF84.8 (*Other pervasive*

developmental disorders). For our analysis, we also included additional neurodevelopmental disorder

codes under the umbrella of 'any neurodevelopmental disorder', including DF95.1 (*chronic motor or*

vocal tic disorder), DF95.2 (*Tourette's syndrome*), DF88 (*Other disorders of psychological*

development), and DF89 (*Unspecified disorder of psychological development*), in addition to ADHD and

autism as previously described.

The ADHD Rating Scale (ADHD-RS) questionnaire was completed by parents to assess the severity of

inattentive and impulsive-hyperactive symptoms (6), and the Social Responsiveness Scale-2 (SRS-2)

was used to assess the severity of autism traits in the whole cohort (7). Symptom loads are derived

from the total scores of the ADHD-RS (Q1-Q18) and SRS-2 questionnaires. Subscales for ADHD-RS

and SRS-2 are utilised in subanalysis. In addition, at 6 years, we evaluated hyperactivity/inattention

problems using the subscale from the Strengths and Difficulties Questionnaire (SDQ), which scores

range from 0 to 10 (49,50).

The Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and

Lifetime Version (K-SADS-PL) (25) was used to assess current and lifetime psychopathology through

a general screening interview and supplementary interview for relevant disorders (51). All K-SADS-PL

interviews were conducted by a trained clinician. If certain thresholds are reached, a supplementary

interview is conducted to assign relevant diagnoses based on all available information. Consensus

diagnoses were made between senior researcher and psychologist with specialty in child and

adolescent psychiatry (JRMJ) and at least two examiners according to both the Diagnostic and

Statistical Manual of Mental Disorders, Fifth Edition (52) and the International Classification of Disorders

10th Revision (ICD-10) of Mental and Behavioural Disorders: Clinical descriptions and diagnostic

guidelines (53). Diagnostic classification was further validated by a professor in child and adolescent

psychiatry (NB). An estimation of interrater reliability on the symptom level was performed based on

video recordings of 10 participants with JRJM as the gold standard. The overall agreement, including

both currently present and not present symptoms, was 99.48% (95%CI 99.25-99.66). The agreement

specifically on present symptoms was 88.48% (95%CI 82.60-92.92).

Food Frequency Questionnaires and Pregnancy Dietary Patterns

At 24 weeks of gestation, upon their recruitment to the COPSAC2010 cohort, mothers were asked to complete a validated semi-quantitative FFQ with a one-month recall period, encompassing 360 items detailing their dietary intake over the previous month. Mothers in COPSAC2010 and DNBC were subsequently excluded from the analysis for reporting unrealistic energy intakes, either below 4,200 kJ/day or exceeding 16,700 kJ/day. Utilised in both the DNBC validation cohort and the COPSAC2010 cohort, this FFQ has been validated in both a group of younger women (54) and for pregnant women (55,56). The timing of FFQ completion at week 25 in the DNBC cohort, closely aligned with the COPSAC2010 cohort's at 24 weeks, and thus facilitates the examination of dietary pattern associations on neurodevelopmental outcomes (45). Mothers reported their intake of foods with natural units like apples, while for items without natural units, such as lasagne, they indicated frequency of consumption. Nutrient intakes were estimated using standard portion sizes and recipes, with frequency categories converted to daily intake. Intakes of various food items were calculated based on standard portion size assumptions, measured in grams per day. Nutrient constituents were then determined using the National Food Institute's Food Composition Databank, version 7 (57). Nutrient constituents were selected for analysis due to its association with physiological and metabolic functions, which provides a perspective on biological mechanisms applicable across various populations. During the COPSYCH clinical assessment at the age of 10, we collected data on the dietary habits of children. The FFQ, encompassing 145 distinct food items, aimed to capture the consistent dietary habits of children. It has been previously validated for use among adolescents aged 12-15 in the DNBC study (58). Intakes of food groups and nutrient components were measured using the same method as the pregnancy questionnaire mentioned above.

In COPSAC2010, principal component analysis (PCA) was used to identify maternal dietary patterns based on the calculated estimates of energy, macronutrient, and micronutrient intake in 613 mothers. In the DNBC cohort, dietary pattern validation was achieved using the principal component model originally trained in COPSAC2010 data, ensuring the identification of directly comparable dietary patterns across the two cohorts. To validate our methodology, we also assessed for associations of a comparable dietary pattern trained within the DNBC. In COPSAC2010, the derived dietary patterns

were associated with estimates for food groups for interpretability. The sum totals of nutrient

constituents were excluded to avoid redundancy in the PCA.

In the VDAART cohort, mothers were asked to complete a semi-quantitative food frequency

questionnaire (FFQ) during the clinical visit corresponding to when the blood metabolome samples were

taken: 10-18 weeks and 32-38 weeks gestation (59). The FFQ captured the average weekly

consumption of each food item(s) over the past year using the following ordinal categories:"Less than

once per week" as 0, "Once per week" as 1, "2-4 times per week" as 2, "Nearly daily or daily" as 3, and

"Twice or more per day" as 4.

DNBC, VDAART and COPSAC2000 Neurodevelopmental Outcomes

In the DNBC cohort, neurodevelopmental outcomes were derived from National registers. Specifically,

outcome data was extracted from the Danish National Patient Register (60), the Danish Psychiatric

Central Research Register (61), the Danish National Prescription Registry (62). Children were defined

as having an ADHD diagnosis if they had received an ADHD diagnosis or redeemed a prescription for

ADHD medication after reaching 3 years of age. The diagnoses were obtained from the Danish National

Patient Register and Danish Psychiatric Central Research Register. These were recorded according to

the International Classification of Diseases Tenth revision (ICD-10) and we defined a case by using the

diagnostic codes from F90.x. Prescriptions of ADHD medication were identified from the Danish

National Prescription Registry using the Anatomical Therapeutic Chemical Classification codes for

methylphenidate (N06BA04), modafinil (N06BA07), and atomoxetine (N06BA09). Similarly, autism

diagnosis was defined as children aged 2 years or older with a diagnosis code of ICD-10: F84.0, F84.1,

F84.5, F84.8, or F84.9, derived from the Danish National Patient Register, or the Danish Psychiatric

Central Research Register. Any neurodevelopmental diagnosis disorder was defined as having an

ADHD, or autism diagnosis, as defined above, or any of the following ICD-10 codes: F80-83 (other

developmental disorder), F84 (Pervasive developmental disorders), (F88-89 (other/unspecified

disorders of psychological development), F95 (tic disorders), F98·8 (ADHD – inattentive type) and F20-

F29 (schizophrenia spectrum disorder). In addition, at 7 years, we evaluated hyperactivity/inattention

problems using the subscale from the SDQ, which scores range from 0 to 10 (49,50).

Parents of VDAART children at the six-, seven- and eight-year follow-up visits were asked if their child

"*had ever received a physician diagnosis of ADD or ADHD*" or "*had ever received a physician diagnosis*

of autism". Our main analysis was on children at the age of 6. Further for an analysis of robustness we

assessed associations on whether children had ever had a diagnosis of ADD/ADHD or autism up to the

age of eight.

In COPSAC2000, participants were asked to complete the Adult ADHD Self-Report Scale v1.1 (ASRS)

at the 18-year clinical cohort visit (63). The ASRS has been validated and demonstrated good reliability

and validity in screening for ADHD in adults. In our analysis, participants received a score of 1 for any

question that deemed a symptom of ADHD (such that total scores could range from 0 to 18) (64). As a

subanalysis we stratified inattention-based questions (Q1-Q4, Q7-Q11) and hyperactivity-impulsivity

questions (Q5-Q6, Q12-Q18).

Blood Metabolome

Untargeted plasma metabolomics data was collected from mothers at mid-pregnancy (24 weeks

gestation) and one week postpartum, and from children at ages 6 months, 18 months, and 6 years in

the COPSAC2010 cohort. A blood sample was collected using an EDTA tube during the visit to the

research clinic site, then centrifuged for 10 minutes at 4000 rpm to extract the plasma. The supernatant

was secured and stored at −80 °C for future analysis. The untargeted metabolomic analysis of the

plasma samples for both COPSAC2010 and the VDAART cohorts were carried out by Metabolon, Inc.

(NC, USA).

For sample preparation, we employed the MicroLab STAR® system from Hamilton Company, which is

an automated process. Each sample was enhanced with recovery standards to ensure quality control

(QC) before metabolites were extracted using methanol. This extraction process involved vigorous

shaking for 2 minutes using a Glen Mills GenoGrinder 2000, followed by centrifugation, to precipitate

proteins. The extract was then divided into four aliquots for further analysis on four different LC-MS/MS

platforms. The aliquots were dried using a TurboVap® (Zymark) to evaporate the organic solvent, then

stored under nitrogen overnight prior to LC-MS/MS preparation.

The analysis through LC-MS/MS was conducted using an ACQUITY Ultra-Performance Liquid

Chromatography (UPLC) system by Waters, Milford, USA, coupled with a Q Exactive™ Hybrid

Quadrupole-Orbitrap™ mass spectrometer, which includes a heated electrospray ionisation (HESI-II)

source, provided by ThermoFisher Scientific, Waltham, Massachusetts, USA. We prepared the sample

extracts in solvent mixes specifically chosen for each of the four LC methods applied: two methods

were reverse phase UPLC-ESI(+) MS/MS for analysing both hydrophilic and hydrophobic molecules;

another was a reverse phase UPLC-(−) MS/MS; and the last was HILIC/UPLC-(−) MS/MS. The mass

spectrometry analysis alternated between full scan MS and data-dependent MSn scans with dynamic

exclusion, covering a scan range from 70 to 1000 m/z for both ion modes.

In terms of data collection and quality control, the raw data was subjected to extraction, peak

identification and followed by QC procedures. The semi-quantification of samples was based on the

area-under-the-curve method. Further details are discussed in our previously published work (65).

Data preprocessing was done by excluding metabolites with >33% missingness. Remaining missing

data was imputed using random forest imputation (missForest package, v1.5) (66) and the metabolome

data was log-transformed, centred and scaled, prior to analysis. A pattern of missingness identified in

the metabolite subset (0.11 [0.02-0.20], p=0.021) suggested under detection in the Western dietary

pattern, with no corresponding bias for neurodevelopmental outcomes or across the full metabolome

(*Table S13*), reinforcing the validity of our imputation approach. The metabolome data for mothers at

mid-pregnancy (24 weeks gestation) had a total of 760 annotated metabolites for analysis. Of these,

744 metabolites overlapped between the 24-week gestation period and one week postpartum, 516

metabolites overlapped with 6-month data, 707 metabolites overlapped with 18-month data and 540

metabolites overlapped with 6-year data.

We used two VDAART blood metabolome pregnancy time points (10-18 weeks and 32-38 weeks),

measured on the same platform as the COPSAC2010 samples, to replicate our findings for ADHD. The

24-week pregnancy time point in COPSAC2010 was compared with those for early pregnancy (10-18

weeks gestation) and late pregnancy (32-38 weeks gestation) in VDAART, identifying 640 and 689

overlapping metabolites, respectively. We further predicted metabolite scores for the VDAART children,

with 523 overlapping metabolites at 1 year, 530 at 3 years, and 677 overlapping metabolites at 6 years.

The metabolite scores were predicted using the model trained on COPSAC2010 data; applied to log-

transformed, centred and scaled VDAART data. The metabolite score predictions were subsequently

scaled, and thus results should be interpreted as per SD change in the given population.

Neonatal Dried Blood Spot samples

DBS samples from COPSAC2010 (*n=677*) and COPSAC2000 (*n=387*) were respectively collected at age 2-3 days and 1-12 days after birth, and stored at -20°C at the Danish National Biobank until analysis. Metabolic profiles of the DBS samples were acquired by liquid chromatography mass spectrometry (LC-MS). Data preprocessing was executed using both XCMS and MZmine, with the quality assessed based on the distribution of pooled samples (38). Metabolite extraction from DBS samples, a 3.2mm punch in diameter, was conducted using a Microlab STAR automated liquid handler from Hamilton Bonaduz AG, Bonaduz, Switzerland. These samples were extracted onto 96-well plates in batches with 100 μL of 80% methanol, specifically designed for analytical processes. Subsequently, 75 μL of the supernatants were shifted to fresh plates, air-dried under a nitrogen atmosphere, and reconstituted in 75 μL of 2.5% methanol. Before injection, 65 μL was transferred onto the final plates. For the analysis, samples from both COPSAC2000 and COPSAC2010 were divided, with the former distributed across six batches and the latter across ten. Each batch or plate comprised eight water blanks, an internal standard mix, four external controls, three paper blanks, four pooled samples, two diluted pools, and 74 cohort samples. All extractions utilised LC-MS grade solvents provided by Thermo Fisher Scientific, Waltham, MA, USA. An addition of 24 isotope-labelled internal standards, encompassing amino acids and acylcarnitines, was made to the extraction solvents. These standards, consistent in concentration across samples, were employed to ensure quality and evaluate the efficacy of batch correction and normalisation that followed. To further gauge the variability in sample preparation, acquisition, and preprocessing, quality control pooled samples (PSs) were periodically assessed throughout the analysis run. Metabolic profiles were generated using a high-resolution Thermo Scientific Q-Exactive Orbitrap mass spectrometer, linked to a Dionex Ultimate 3000 UPLC. This complex procedure involved a series of specific injection, gradient operation, and parameters for mass spectrometric analysis. Preprocessing of the acquired data involved the use of software like XCMS, MZmine, and MSconvert, with specific protocols established for peak detection, alignment, deconvolution, and filtering. Ensuring data quality was paramount, and this was maintained through the use of internal standards and a series of checks, including principal component analysis (PCA) to confirm the clustering of pooled samples. For a more detailed insight into the equipment settings, data preprocessing steps, and quality controls, refer to the specific sections on mass spectrometry settings, LC-MS/MS data preprocessing, and quality control in the supplementary information. Further in-depth

description of sample preparation, LC-MS metabolic profiling, and data pre-processing for both cohorts

can be found in previous work (38).There were 2313 features detected in COPSAC2010 and 2363

features in COPSAC2000. As the majority of features were unnamed, we merged both datasets using

an inexact matching criterion (mass ±0.01, retention time ± 0.1) using the fuzzyjoin R package (v0.1.6)

(67) and subsequently found 1253 overlapping metabolites between cohorts. For further robustness,

we applied a further filter, only retaining features that had a cross-correlation between cohorts of >0.4,

ending with 951 overlapping features between cohorts.

Information on Covariates

In our multivariable analysis, we included the following covariates for COPSAC2010: pre-pregnancy

maternal BMI, social circumstances (the first principal component of household income, maternal

education level, and maternal age at birth), child sex, birth weight, gestational age, smoking during

pregnancy, antibiotic use during pregnancy, pre-eclampsia and a child Western dietary pattern,

assessed by a FFQ from children at 10 years old. Missing covariate data was imputed, based on the

available covariate information available using the imputePCA function with one component from the

missMDA (v1.18) R package.

Additionally, we conducted sensitivity analysis in COPSAC2010 to explore the influence of the following

variables: the results of two randomised controlled trials conducted within the COPSAC2010 cohort

(n3-LCPUFA supplementation and high-dose vitamin D during pregnancy) (42), total energy intake

derived from the maternal FFQ, maternal ADHD genetic risk, intake of prenatal supplements, and

genomic PCs. Specifically, adjustment of intake of prenatal supplements was conducted by adjusting

for the first seven principal components (explaining 78.6% of the total variance) of the estimated intakes

of 31 vitamins, minerals and fatty acids, recorded at the time of the 24 week FFQ, and whether prenatal

supplements were taken (yes (94.1%) or no (5.9%)). Missing data were imputed using the same

approach described above from the missMDA R package.

Covariates used in multivariable analysis for the DNBC included pre-pregnancy maternal BMI, parental

social group (high, medium, skilled, student, unskilled, unemployed), maternal age, child sex, birth

weight, gestational age and smoking during pregnancy. Missing covariate data were imputed based on

existing covariates using multiple imputation as implemented by the PROC MI procedure in SAS

(version 9.1, SAS Institute, Cary, NC).

Covariates used in multivariable analysis for the VDAART included pre-pregnancy maternal BMI, social

circumstances (the first principal component of household income, maternal education level, and

maternal age at birth), child sex, birth weight, gestational age, smoking during pregnancy, pre-

eclampsia, and race. Missing covariate data was imputed, based on the available covariate information

using the imputePCA function with one component from the missMDA (v1.18) R package.

Covariates used in multivariable analysis for COPSAC2000 included social circumstances (the first

principal component of household income, maternal education level, and maternal age at birth), child

sex, birth weight, antibiotics during pregnancy and smoking during pregnancy.

The child sex variable in COPSAC2010, the DNBC, COPSAC2000 and VDAART was interpreted as

sex assigned at birth.

Polygenic Risk Scores

Maternal and child genotypes in the COPSAC2010 cohort were analysed using the Illumina Infinium

HumanOmniExpressExome BeadChip. To calculate PRS for ADHD and autism, we used data from

genome-wide association meta-analyses of diagnosed ADHD cases ($n=20,183$) and controls

($n=35,191$) (68) and autism cases ($n=18,381$) and controls ($n=27,969)$ (69).

The software package Polygenic risk score continuous shrinkage (CS) was used for PRS construction

through regularising SNP effects using a shrinkage prior (70). PRS-CS uses a linkage disequilibrium

(LD) reference panel constructed via European ancestry samples from the 1000 genomes project. We

used the automatic estimation of the polygenicity parameter (phi). Subsequent to SNP effect adjustment

with PRS-CS, we used the software PLINK2 (71) to aggregate SNP effects into PRSs for each

individual. The scores were scaled to mean 0 and SD 1 for each phenotype.

Statistical Analysis

Logistic regression models were used to determine the associations of maternal dietary patterns on

neurodevelopmental disorders, and linear regression models were used to assess the associations of

maternal dietary patterns on parentally reported symptom loads for ADHD and autism. All multivariable

models were adjusted for the previously mentioned covariates. Dietary principal components and

metabolite scores were scaled to enhanced interpretation (Odds ratios and estimates are interpreted

as per SD change). We used linear interaction models to examine the modulating effects of genetics,

child sex and maternal BMI on neurodevelopmental outcomes. All interaction models were multivariable

(see `Information on covariates`), additionally including genetic risk (see `Polygenic Risk Scores`). We

excluded five individuals from the analysis. Specifically, we removed the second twin from twin pairs

since the exposure of interest was not independent. However, non-twin sibling pairs were retained in

the analysis, as the exposure and outcome measures were independently assessed for each sibling.

We used Gaussian graphical network models via the framework described by Williams and Rast (72).

Gaussian graphical models show the non-zero relationships (95% CI) between the dietary pattern,

neurodevelopmental outcomes and model covariates, controlling for the linear effects of all covariates

expressed as partial correlations. We integrated gestational age and birthweight to refine our Gaussian

graphical network models, as these variables are highly collinear (73). From these models, significant

associations in the resulting precision matrices were visualised as interconnected network diagrams

utilising the ggraph (v2.1.0), igraph (v1.2.11), and qgraph (v1.9.2) libraries in R.

We used the caret package (v6.0.90) to establish Western dietary pattern metabolite scores (WDP-

MS), via sparse partial least squares regression on the COPSAC2010 metabolomics datasets, with the

pregnancy Western dietary pattern as the response. Individual models were created for predicting

WDP-MS at other timepoints, using the subset of overlapping metabolites (See `Blood Metabolome`).

To improve interpretability and reduce the risk of overfitting, we used single-component models,

applying cross-validated predictions (repeated cv, number of segments=5, repeats=10). After reviewing

models that varied in sparsity (incremented by 0.1 from 0 to 1), we opted for the model with the lowest

root-mean-standard error for cross-validation (RMSECV) as our selection criteria. For external

validation between COPSAC2010 and VDAART, we adjusted our model parameters to balance against

overfitting whilst ensuring optimal performance, leading to the selection of models that were within +0.01

RMSECV of the best-performing model. We similarly trained a sPLS model in the COPSAC2010 cohort

on the Western dietary pattern from DBS metabolic profiles that overlapped with the COPSAC2000

cohort.

To elucidate the role of metabolites as potential biomarkers or mediators in the association between a

Western dietary pattern and neurodevelopmental disorders, we employed a systematic backward

elimination strategy. This approach was designed to iteratively exclude metabolites, aiming to identify

those with the most profound mediating influence on the outcome. We employed 10,000 iterations for

each step of this elimination. We used two linear models: one linking a composite metabolite score to

the Western dietary pattern and covariates, and another assessing its mediating role between dietary

patterns and neurodevelopmental outcome. This causal mediation analysis was conducted with the

mediation package in R (v4.5.0).

When comparing the associations of the mother and child WDP-MS in logistic regression, we utilised

the imputePCA function from the missMDA package (v1.18) (74) to impute missing data with one

component (12.5% in COPSAC2010). This was done using the available metabolite scores as a

reference. Linear mixed models with variable slopes and intercepts were applied to the WDP-MS data,

integrating gestational age alongside chronological age. The slopes and intercepts were treated as

random effects, allowing for modelling of the longitudinal association of the identified maternal dietary

pattern on neurodevelopmental outcomes. Accordingly, the random effects were extracted for

inference, the "lme4" R- package (1.1.28) was used for modelling (75), both slopes and intercepts were

scaled (estimates are interpreted as per SD change).

A significance level of 0.05 was used in all analyses and false-discovery rate control (FDR) applied

where relevant (<0.05). All data analyses were performed with the statistical software R version 4.1.1.

Other R packages utilised in this analysis include tidyverse (v1.3.1), dplyr (v1.0.10), broom (v0.7.12),

lubridate (v1.8.0), ggpubr (v0.4.0) and tableone (v0.13.0).

Data Availability: Participant-level personally identifiable data are protected under the Danish Data

Protection Act and European Regulation 2016/679 of the European Parliament and of the Council

(GDPR) that prohibit distribution even in pseudo-anonymized form. However, participant-level data can

be made available under a data transfer agreement as part of a collaboration effort.

Code Availability: The custom code employed in this research is freely accessible to the public for

transparency and reproducibility purposes.

Methods-only References

42. Bisgaard H, Vissing NH, Carson CG, Bischoff AL, Følsgaard NV, Kreiner-Møller E, et al. Deep phenotyping of the unselected COPSAC $_{2010}$ birth cohort study [Internet]. Vol. 43, Clinical & Experimental Allergy. 2013. p. 1384–94. Available from: http://dx.doi.org/10.1111/cea.12213

43. Mohammadzadeh P, Rosenberg JB, Vinding R, Møllegaard Jepsen JR, Lindberg U, Følsgaard N, et al. Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYCH study protocol. BMJ Open. 2022 Feb 1;12(2):e047706.

44. Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, Andersen AM, et al. The Danish National Birth Cohort--its background, structure and aim. Scand J Public Health. 2001 Dec;29(4):300–7.

45. Olsen SF, Mikkelsen TB, Knudsen VK, Orozova-Bekkevold I, Halldórsson TI, Strøm M, et al. Data collected on maternal dietary exposures in the Danish National Birth Cohort. Paediatr Perinat Epidemiol. 2007 Jan;21(1):76–86.

46. Litonjua AA, Lange NE, Carey VJ, Brown S, Laranjo N, Harshfield BJ, et al. The Vitamin D Antenatal Asthma Reduction Trial (VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D supplementation in pregnancy for the primary prevention of asthma and allergies in children. Contemp Clin Trials. 2014 May;38(1):37–50.

47. Kelly RS, Boulin A, Laranjo N, Lee-Sarwar K, Chu SH, Yadama AP, et al. Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire. Metabolites [Internet]. 2019 Mar 5;9(3). Available from: http://dx.doi.org/10.3390/metabo9030042

48. Bisgaard H. The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol. 2004 Oct;93(4):381–9.

49. Obel C, Heiervang E, Rodriguez A, Heyerdahl S, Smedje H, Sourander A, et al. The Strengths and Difficulties Questionnaire in the Nordic countries. Eur Child Adolesc Psychiatry. 2004;13 Suppl 2:II32–9.

50. Sveen TH, Berg-Nielsen TS, Lydersen S, Wichstrøm L. Detecting psychiatric disorders in preschoolers: screening with the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):728–36.

51. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980–8.

52. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. 2022. 1120 p.

53. World Health Organization. The International Statistical Classification of Diseases and Health Related Problems ICD-10: Tenth Revision. Volume 2: Instruction Manual. World Health Organization; 2004. 198 p.

54. Friis S, Kruger Kjaer S, Stripp C, Overvad K. Reproducibility and relative validity of a self-administered semiquantitative food frequency questionnaire applied to younger women. J Clin Epidemiol. 1997 Mar;50(3):303–11.

55. Mikkelsen TB, Olsen SF, Rasmussen SE, Osler M. Relative validity of fruit and vegetable intake estimated by the food frequency questionnaire used in the Danish National Birth Cohort. Scand J Public Health. 2007;35(2):172–9.

56. Mikkelsen TB, Osler M, Olsen SF. Validity of protein, retinol, folic acid and n-3 fatty acid intakes estimated from the food-frequency questionnaire used in the Danish National Birth

Cohort. Public Health Nutr. 2006 Sep;9(6):771–8.

57. Paperpile [Internet]. [cited 2023 Oct 26]. Danish Food Composition Data, Version 7. Available
from: https://paperpile.com/app/p/49f46071-353d-0183-9823-b8b1c9c5898d

58. Bjerregaard AA, Halldorsson TI, Kampmann FB, Olsen SF, Tetens I. Relative validity of a
web-based food frequency questionnaire for Danish adolescents. Nutr J. 2018 Jan 12;17(1):9.

59. Kachroo P, Kelly RS, Mirzakhani H, Lee-Sarwar K, Chawes BL, Blighe K, et al. Fish oil
supplementation during pregnancy is protective against asthma/wheeze in offspring. J Allergy
Clin Immunol Pract. 2020 Jan;8(1):388–91.e2.

60. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The
Danish National Patient Registry: a review of content, data quality, and research potential. Clin
Epidemiol. 2015 Nov 17;7:449–90.

61. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand
J Public Health. 2011 Jul;39(7 Suppl):54–7.

62. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data
Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017 Jun
1;46(3):798–798f.

63. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health
Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the
general population. Psychol Med. 2005 Feb;35(2):245–56.

64. Adler LA, Faraone SV, Sarocco P, Atkins N, Khachatryan A. Establishing US norms for the
Adult ADHD Self-Report Scale (ASRS-v1.1) and characterising symptom burden among adults
with self-reported ADHD. Int J Clin Pract. 2019 Jan;73(1):e13260.

65. Rago D, Rasmussen MA, Lee-Sarwar KA, Weiss ST, Lasky-Su J, Stokholm J, et al. Fish-oil
supplementation in pregnancy, child metabolomics and asthma risk. EBioMedicine. 2019
Aug;46:399–410.

66. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-
type data. Bioinformatics. 2012 Jan 1;28(1):112–8.

67. Website [Internet]. Available from: Robinson D Bryan J Elias. 2020. "Fuzzyjoin: Join Tables
Together on Inexact Matching. 2020" Version 0.1.6 (May). https://cran.r-
project.org/web/packages/fuzzyjoin/index.html.

68. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the
first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019
Jan;51(1):63–75.

69. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common
genetic risk variants for autism spectrum disorder. Nat Genet. 2019 Mar;51(3):431–44.

70. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression
and continuous shrinkage priors. Nat Commun. 2019 Apr 16;10(1):1776.

71. PLINK 2.0 [Internet]. [cited 2023 Mar 29]. Available from: https://www.cog-
genomics.org/plink/2.0/

72. Williams DR, Rast P. Back to the basics: Rethinking partial correlation network methodology.
Br J Math Stat Psychol. 2020 May;73(2):187–212.

73. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves
based on ultrasonically estimated foetal weights. Acta Paediatr. 1996 Jul;85(7):843–8.

74. Josse J, Husson F. **missMDA**: A Package for Handling Missing Values in Multivariate Data
Analysis [Internet]. Vol. 70, Journal of Statistical Software. 2016. Available from:

http://dx.doi.org/10.18637/jss.v070.i01

75. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using**lme4**
[Internet]. Vol. 67, Journal of Statistical Software. 2015. Available from:
http://dx.doi.org/10.18637/jss.v067.i01

Supplementary Figure S1. Biplot of the first two principal components (PCs) from the maternal food frequency questionnaire-derived nutrient constituents. PC2 (Western dietary pattern) is significantly associated with any neurodevelopmental disorder (OR 1.53 [1.17 - 2.00], p=0.002), ADHD (OR 1.66 [1.21 - 2.27], p = 0.002), and autism diagnosis (OR 2.22 [1.33 - 3.74], p = 0.002). PC1 is not significantly associated with any neurodevelopmental disorders (p > 0.288). Further details of the loadings for each of the 95 nutrient constituents can be viewed in supplementary table 2.

Supplementary Figure S2. Biplot of the first two principal components from the maternal FFQ-derived nutrient constituents **A)** Nutrient constituents are categorised into fatty acids, amino acids, sugars, minerals and vitamins. Fatty acids are a key determinant of PC2 (Western dietary pattern) **B)** Stratified further by fatty acid type, saturated fatty acids are most associated with PC2 (Western dietary pattern).

Supplementary Figure S3. Comparison of maternal blood metabolomes at three different pregnancy timepoints from two mother-child cohorts. Top panels show a Principal Component Analysis (PCA) scoreplot on all metabolites, as well as the selected metabolite scores for the COPSAC2010 vs VDAART 10-18 weeks (left) and COPSAC2010 vs VDAART 32-38 weeks (right). Bottom panels show the relative variation per metabolite computed by the ratio of sums of squares (SSQ_{time} / $SSQ_{residual}$) from a one-way anova model with Time/Cohort at predictor and Comparison of per metabolite standard deviation within cohort relative to 24 week gestation pregnancy time point from COPSAC2010 for the COPSAC2010 vs VDAART 10-18 weeks (left) and COPSAC2010 vs VDAART 32-38 weeks (right).

VDAART Pregnancy FFQs Associate with Western Dietary Pattern Metabolite Scores

Associations

- 10–18w positive association
- 10–18w negative association
- 32–38w positive association
- 32–38w negative association
- 10–18w no association
- 32–38w no association

Supplementary Figure S4. Associations between dietary intake from food frequency questionnaires (FFQs) during pregnancy and Western Dietary Pattern Metabolite Scores (WDP-MS) at two distinct timepoints (10-18 weeks and 32-38 weeks) in the VDAART cohort. The depicted associations, based on the VDAART cohort, were assessed using COPSAC2010 cohort-trained models that shared overlapping metabolites.

ADHD Mediation by Metabolites: Models Based on COPSAC2010 with VDAART Timepoints

Supplementary Figure S5. Metabolites associated with a Western dietary pattern at VDAART gestational timepoints (10-18 weeks and 32-38 weeks), based on models from the COPSAC2010 cohort. The selected metabolite scores are depicted by bars, distinguished by their metabolic pathway. Striped bars indicate metabolites that mediate the association with ADHD Diagnosis in COPSAC2010, while solid bars signify non-mediating metabolites. The directionality of the bars represents the positive or negative metabolite score. Metabolite scores from VDAART are colour-coded for each timepoint: 10-18 weeks (green) and 32-38 weeks (purple).

Supplementary Figure S6. Comparative analysis of metabolomic data across newborn dry blood spots from the COPSAC2010 and COPSAC2000 mother-child cohorts. Principal Component Analysis (PCA) plots illustrate the distribution and separation of metabolomic data between cohorts. Panels A-C represent overlapping metabolomes used in our analysis (n=951, n=774, n=626), showcasing subsets of metabolites selected based on varying degrees of correlation and distributional similarity between cohorts. **A:** displays the PCA for metabolites with correlations greater than 0.4 (n=951), **B:** Correlations greater than 0.6 (n=774), and **C:** Metabolites with a correlation greater than 0.6 passing the two-sample Kolmogorov-Smirnov test with a threshold of >=0.05 (n=626).

Sex Stratified: Western Dietary Pattern Associations with Neurodevelopmental Disorders

Supplementary Figure S7. Modulation of the Western Dietary Pattern, Stratified by Child Sex, on Neurodevelopmental Outcomes. Odds ratio estimates of ADHD (**A**) and autism diagnoses (B) based on interactions of the Western dietary pattern, maternal pre-pregnancy BMI (split at median value 23.7), and child's polygenic risk score (PRS) (median split) for ADHD and autism, stratified by child sex. Estimates for ADHD and autism symptom loads based on the Western dietary pattern, considering tertiles of maternal pre-pregnancy BMI (<22.2, 22.2-25.4, >25.4) and child's PRS for ADHD and autism, stratified by child sex. Stars represent significance levels: * indicates $p < 0.05$, ** indicates $p < 0.01$, and *** indicates $p < 0.001$, with "NS" denoting non-significant results ($p \geq 0.05$). Further details, including the individual associations of these modulating factors, can be found in Table S11.

Western Dietary Pattern Metabolite Score Associations with Neurodevelopmental Disorders

Supplementary Figure S8. Modulation of the Western Dietary Pattern Metabolite Score on Neurodevelopmental Outcomes in COPSAC2010 Cohort. Odds ratio estimates for ADHD (A) and autism diagnoses (B) based on interactions of the Western dietary pattern metabolite score, maternal pre-pregnancy BMI (split at median value 23.7), and child's polygenic risk score (PRS) (median split) for ADHD and autism. Estimates for ADHD (C) and autism (D) symptom loads are based on the Western dietary pattern metabolite score, considering tertiles of maternal pre-pregnancy BMI and child's PRS for ADHD and autism. Stars represent significance levels: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001, with "NS" denoting non-significant results (p ≥ 0.05). Further details, including the individual associations of these modulating factors, can be found in Table S11.

Supplementary Figure S9. The Western dietary patterns metabolite scores association with ADHD and autism symptom loads, considering standard clinical classifications of maternal pre-pregnancy BMI. Panels A and D represent ADHD and autism symptom loads respectively, stratified by low/high genetic risk (median cut). Panels B and E further contextualise these associations based on maternal pre-pregnancy BMI categories. Panels C and F again contextualise these associations by stratifying by child sex (male sex shown).

Cohort Characteristics	Participated	Not Participated
n =	600	95
Age (mean (SD))	10.3 (0.4)	-
Male Sex (%)	310 (51.7)	47 (49.5)
Caucasian Race (%)	573 (95.5)	93 (97.9)
Income type (%)		
Low (<50,000 euro)	48 (13.0)	12 (18.2)
Medium (50,000 - 110,000 euro)	114 (31.0)	17 (25.8)
High (>110,000 euro)	206 (56.0)	37 (56.1)
Maternal Education Level at Birth		
Low (primary, secondary, or college graduate)	46 (7.7)	5 (5.3)
Medium (tradesman or bachelor's degree)	373 (62.2)	68 (71.6)
High (Masters degree)	181 (30.2)	22 (23.2)
Maternal age at birth (mean (SD))	32.4 (4.3)	31.8 (4.5)
Birthweight (mean (SD))	3.5 (0.5)	3.5 (0.6)
Gestational age (mean (SD))	279 (12)	278 (11)
Cesarean section (%)	125 (20.8)	25 (26.3)
Maternal smoking during pregnancy (%)	44 (7.3)	10 (10.5)
Solely Breastfed (mean (SD))	105 (59)	94 (65)
Siblings (mean (SD))	1.6 (0.9)	1.6 (0.8)
Pregnancy Western Dietary Pattern (mean (SD))	0.02 (0.99)	-0.20 (1.04)
Pregnancy Western Dietary Pattern Metabolite Score (mean (SD))	-0.02 (0.99)	0.10 (1.04)

Supplementary Table S1. Cohort characteristics stratified by participation in the COPSAC2010 10 year clinical visit. Low, medium, and high income are defined as <50,000, 50,000 - 110,000, and >110,000 euro respectively. Low, medium and high level educational attainment are defined as "primary, secondary, or college graduate", "tradesman or bachelor's degree" and "Masters degree", respectively.

Cohort Characteristics	Female	Male
n =	290	310
Age (mean (SD))	10.3 (0.4)	10.3 (0.3)
Caucasian Race (%)	279 (96.2)	294 (94.8)
Income type (%)		
Low (<50,000 euro)	30 (10.3)	18 (5.8)
Medium (50,000 - 110,000 euro)	152 (52.4)	168 (54.2)
High (>110,000 euro)	108 (37.2)	124 (40.0)
Maternal Education Level at Birth		
Low (primary, secondary, or college graduate)	24 (8.3)	22 (7.1)
Medium (tradesman or bachelor's degree)	172 (59.3)	201 (64.8)
High (Masters degree)	94 (32.4)	87 (28.1)
Maternal age at birth (mean (SD))	32.4 (4.2)	32.3 (4.5)
Birthweight (mean (SD))	3.5 (0.5)	3.6 (0.6)
Gestational age (mean (SD))	280 (10)	279 (12)
Cesarean section (%)	54 (18.6)	71 (22.9)
Maternal smoking during pregnancy (%)	22 (7.6)	22 (7.1)
Solely Breastfed (mean (SD))	106 (59)	104 (58)
Siblings (mean (SD))	1.6 (0.9)	1.6 (0.8)

Supplementary Table S2. Cohort characteristics stratified by child sex in COPSYCH 10 year clinical visit. Low, medium, and high income are defined as *<50,000, 50,000 - 110,000, and >110,000 euro,* respectively. Low, medium and high level educational attainment are defined as "*primary, secondary, or college graduate*", "*tradesman or bachelor's degree*" and "*Masters degree*", respectively.

	Mean (SD)	PC1 Loadings	PC2 Loadings	Category
FFQ nutrient constituents	-	-	-	
Added sugar (g/day) (mean (SD))	36.04 (26.25)	0.033	0.123	Sugars
Dietary fiber (g/day) (mean (SD))	27.92 (9.76)	0.097	-0.125	Sugars
Alcohol (g/day) (mean (SD))	0.41 (0.75)	0.015	0.013	Sugars
Ashes (g/day) (mean (SD))	20.18 (4.99)	0.142	-0.018	Minerals
Water (g/day) (mean (SD))	2817.43 (740.48)	0.085	-0.072	Minerals
Vitamin A (RE/day) (mean (SD))	824.74 (368.58)	0.085	0.01	Vitamins
Retinol (µg/day) (mean (SD))	490.63 (241.14)	0.085	0.134	Vitamins
Betacarotene (µg/day) (mean (SD))	3958.40 (3258.49)	0.038	-0.106	Vitamins
Vitamin D (µg/day) (mean (SD))	4.86 (2.81)	0.071	-0.087	Vitamins
Vitamin D3 (cholecalciferol) (µg/day) (mean (SD))	1.11 (0.70)	0.08	-0.03	Vitamins
25-hydroxycholecalciferol - a metabolically activated form of cholecalciferol (Vitamin D3) (µg/day) (mean (SD))	0.03 (0.02)	0.048	0.086	Vitamins
Vitamin E (a-TE/day) (mean (SD))	7.93 (2.95)	0.099	-0.045	Vitamins
Alphatocoferol (mg/day) (mean (SD))	7.30 (2.82)	0.097	-0.044	Vitamins
Vitamin K (µg/day) (mean (SD))	86.50 (53.03)	0.052	-0.102	Vitamins
Vitamin B1 (thiamin) (mg/day) (mean (SD))	1.39 (0.38)	0.13	-0.063	Vitamins
Vitamin B2 (riboflavin) (mg/day) (mean (SD))	1.86 (0.66)	0.115	0.002	Vitamins
Niacin equivalents (NE/day) (mean (SD))	26.45 (6.40)	0.142	-0.045	Vitamins
Niacin (mg/day) (mean (SD))	14.49 (3.72)	0.126	-0.074	Vitamins
Tryptophan (mg/day) (mean (SD))	14.68 (4.00)	0.138	-0.004	Amino Acids
Vitamin B6 (mg/day) (mean (SD))	1.61 (0.42)	0.135	-0.111	Vitamins

Pantothenic acid (mg/day) (mean (SD))	6.24 (1.73)	0.134	-0.049	Vitamins
Biotin (µg/day) (mean (SD))	42.94 (13.22)	0.128	-0.068	Vitamins
Folate (µg/day) (mean (SD))	344.59 (101.24)	0.115	-0.108	Vitamins
Vitamin B12 (µg/day) (mean (SD))	5.64 (2.14)	0.116	-0.017	Vitamins
Vitamin C (mg/day) (mean (SD))	140.14 (71.37)	0.061	-0.138	Vitamins
L-ascorbic acid (mg/day) (mean (SD))	136.31 (65.88)	0.063	-0.14	Vitamins
L-dehydroascorbic acid (mg/day) (mean (SD))	13.79 (7.42)	0.05	-0.115	Vitamins
Sodium (mg/day) (mean (SD))	2956.73 (813.05)	0.124	0.043	Minerals
Potassium (mg/day) (mean (SD))	3584.14 (941.59)	0.131	-0.083	Minerals
Calcium (mg/day) (mean (SD))	1237.53 (454.19)	0.103	0.005	Minerals
Magnesium (mg/day) (mean (SD))	399.47 (108.31)	0.126	-0.106	Minerals
Phosphor (mg/day) (mean (SD))	1654.26 (460.76)	0.135	-0.03	Minerals
Iron (mg/day) (mean (SD))	11.22 (2.89)	0.124	-0.074	Minerals
Copper (mg/day) (mean (SD))	4.88 (1.52)	0.055	-0.095	Minerals
Zink (mg/day) (mean (SD))	12.01 (2.98)	0.141	-0.03	Minerals
Iodine (µg/day) (mean (SD))	302.03 (120.03)	0.092	-0.02	Minerals
Manganese (mg/day) (mean (SD))	5.23 (2.06)	0.09	-0.122	Minerals
Chromium (µg/day) (mean (SD))	32.41 (10.28)	0.107	-0.058	Minerals
Selenium (µg/day) (mean (SD))	47.23 (12.57)	0.137	-0.052	Minerals
Nickel (µg/day) (mean (SD))	149.55 (52.65)	0.088	-0.115	Minerals
Fructose (g/day) (mean (SD))	13.72 (6.81)	0.05	-0.158	Sugars
Glucose (g/day) (mean (SD))	12.98 (6.50)	0.052	-0.135	Sugars
Lactose (g/day) (mean (SD))	23.29 (15.87)	0.073	0.028	Sugars
Maltose (g/day) (mean (SD))	2.26 (1.19)	0.056	0.01	Sugars

Sucrose (g/day) (mean (SD))	27.99 (12.07)	0.056	-0.01	Sugars
Starch (g/day) (mean (SD))	99.95 (35.10)	0.09	-0.022	Sugars
C4:0 (Butyric acid, Butanoic acid) (g/day) (mean (SD))	0.97 (0.54)	0.081	0.244	Fatty Acids
C6:0 (Caproic acid, Hexanoic acid) (g/day) (mean (SD))	1.01 (0.58)	0.079	0.243	Fatty Acids
C8:0 (Caprylic acid, Octanoic acid) (g/day) (mean (SD))	0.57 (0.33)	0.079	0.232	Fatty Acids
C10:0 (Capric acid, Decanoic acid) (g/day) (mean (SD))	0.84 (0.46)	0.082	0.243	Fatty Acids
C12:0 (Lauric acid, Dodecanoic acid) (g/day) (mean (SD))	1.26 (0.54)	0.093	0.215	Fatty Acids
C14:0 (Myristic acid, Tetradecanoic acid) (g/day) (mean (SD))	3.17 (1.44)	0.09	0.233	Fatty Acids
C15:0 (Pentadecylic acid, Pentadecanoic acid) (g/day) (mean (SD))	0.01 (0.01)	0.041	-0.018	Fatty Acids
C16:0 (Palmitic acid, Hexadecanoic acid) (g/day) (mean (SD))	15.63 (5.31)	0.106	0.202	Fatty Acids
C17:0 (Margaric acid, Heptadecanoic acid) (g/day) (mean (SD))	0.02 (0.01)	0.043	-0.006	Fatty Acids
C18:0 (Stearic acid, Octadecanoic acid) (g/day) (mean (SD))	6.70 (2.56)	0.095	0.195	Fatty Acids
C20:0 (Arachidic acid, Eicosanoic acid) (g/day) (mean (SD))	0.11 (0.06)	0.08	0.154	Fatty Acids
C22:0 (Behenic acid, Docosanoic acid) (g/day) (mean (SD))	0.05 (0.04)	0.046	0.01	Fatty Acids
C24:0 (Lignoceric acid, Tetracosanoic acid) (g/day) (mean (SD))	0.03 (0.03)	0.039	-0.091	Fatty Acids
C14:1, n-5 (Myristoleic acid) (g/day) (mean (SD))	0.37 (0.17)	0.083	0.231	Fatty Acids
C16:1, n-7 (Palmitoleic acid) (g/day) (mean (SD))	1.27 (0.38)	0.11	0.144	Fatty Acids
C18:1, n-9 (Oleic acid, Elaidic acid) (g/day) (mean (SD))	22.76 (7.61)	0.112	0.125	Fatty Acids
C18:1, n-7 (Vaccenic acid) (g/day) (mean (SD))	0.12 (0.05)	0.089	-0.049	Fatty Acids
C20:1, n-11 (Gadoleic acid) (g/day) (mean (SD))	0.52 (0.21)	0.105	0.113	Fatty Acids
C22:1, n-9 (Erucic acid) (g/day) (mean (SD))	0.02 (0.04)	0.028	-0.041	Fatty Acids
C22:1, n-11 (Cetoleic acid) (g/day) (mean (SD))	0.14 (0.17)	0.05	-0.063	Fatty Acids
C24:1, n-9 (Nervonic acid) (g/day) (mean (SD))	0.02 (0.02)	0.061	-0.09	Fatty Acids
C18:2, n-6 (Linoleic acid) (g/day) (mean (SD))	9.44 (3.25)	0.108	-0.019	Fatty Acids

C18:3, n-3 (Alpha-linolenic acid ALA) (g/day) (mean (SD))	1.92 (0.72)	0.107	0.018	Fatty Acids
C18:4, n-3 (Stearidonic acid SDA, Moroctic acid) (g/day) (mean (SD))	0.05 (0.05)	0.057	-0.08	Fatty Acids
C20:4, n-6 (Arachidonic acid AA) (g/day) (mean (SD))	0.05 (0.02)	0.074	-0.026	Fatty Acids
C20:5, n-3 (Eicosapentaenoic acid EPA, Timnodonic acid) (g/day) (mean (SD))	0.15 (0.11)	0.064	-0.117	Fatty Acids
C22:5, n-3 (Docosapentaenoic acid DPA, Clupanodonic acid) (g/day) (mean (SD))	0.04 (0.03)	0.063	-0.097	Fatty Acids
C22:6, n-3 (Docosahexaenoic acid DHA, Cervonic acid) (g/day) (mean (SD))	0.36 (0.24)	0.069	-0.102	Fatty Acids
Other fatty acids (g/day) (mean (SD))	0.17 (0.07)	0.087	-0.073	Fatty Acids
Trans fatty acids, total (g/day) (mean (SD))	1.61 (0.78)	0.084	0.24	Fatty Acids
Cholesterol (mg/day) (mean (SD))	306.56 (111.46)	0.104	0.143	Fatty Acids
Isoleucine (mg/day) (mean (SD))	3257.44 (895.38)	0.137	0.009	Amino Acids
Leucine (mg/day) (mean (SD))	5356.46 (1490.08)	0.136	0.011	Amino Acids
Lysine (mg/day) (mean (SD))	4771.66 (1352.94)	0.131	0.006	Amino Acids
Methionine (mg/day) (mean (SD))	1552.75 (421.81)	0.136	0.007	Amino Acids
Cystine (mg/day) (mean (SD))	667.43 (183.60)	0.134	-0.028	Amino Acids
Phenylalanine (mg/day) (mean (SD))	3059.71 (833.10)	0.138	0.004	Amino Acids
Tyrosine (mg/day) (mean (SD))	2295.78 (659.79)	0.133	0.014	Amino Acids
Threonine (mg/day) (mean (SD))	2615.14 (699.25)	0.139	-0.002	Amino Acids
Tryptophan (mg/day) (mean (SD))	802.48 (216.52)	0.138	0.004	Amino Acids
Valine (mg/day) (mean (SD))	4098.35 (1106.25)	0.138	0.005	Amino Acids
Arginine (mg/day) (mean (SD))	3814.66 (954.91)	0.138	-0.049	Amino Acids
Histidine (mg/day) (mean (SD))	1923.77 (502.98)	0.139	0.008	Amino Acids
Alanine (mg/day) (mean (SD))	3404.72 (833.44)	0.141	-0.023	Amino Acids
Asparagine acid (mg/day) (mean (SD))	6346.65 (1582.54)	0.141	-0.021	Amino Acids
Glutamic acid (mg/day) (mean (SD))	12803.38 (3446.26)	0.137	0.015	Amino Acids

Glycine (mg/day) (mean (SD))	2919.02 (713.39)	0.136	-0.023	Amino Acids
Proline (mg/day) (mean (SD))	4841.23 (1437.50)	0.13	0.031	Amino Acids
Serine (mg/day) (mean (SD))	3421.27 (925.75)	0.139	0.007	Amino Acids

Supplementary Table S3. Descriptive summary statistics for nutrients derived from maternal food frequency questionnaires in pregnancy and principal component loadings for principal component 1 and 2 in the COPSAC2010 cohort.

Supplement Intake at 24 Weeks Gestation	Mean (SD)	Taking Supplement
Vitamins	-	-
Vitamin A (µg) (mean (SD))	446.75 (256.98)	447
Vitamin B1, Thiamin (mg) (mean (SD))	2.23 (13.57)	449
Vitamin B2, Riboflavin (mg) (mean (SD))	1.73 (2.11)	449
Vitamin B6 (mg) (mean (SD))	2.24 (5.37)	449
Vitamin B12 (µg) (mean (SD))	2.06 (1.43)	446
Folic acid (µg) (mean (SD))	326.82 (161.14)	447
Dietary folate equivalents (µg) (mean (SD))	653.65 (322.28)	447
Niacin (mg) (mean (SD))	16.22 (10.20)	447
Pantothenic acid (mg) (mean (SD))	6.20 (4.64)	447
Biotin (µg) (mean (SD))	17.75 (36.49)	142
Vitamin C (mg) (mean (SD))	92.96 (73.19)	462
Vitamin D (µg) (mean (SD))	10.50 (7.20)	459
Vitamin E (mg) (mean (SD))	11.57 (14.91)	448
Vitamin K (µg) (mean (SD))	48.93 (47.54)	277
Minerals	-	-
Calcium (mg) (mean (SD))	210.48 (320.68)	208
Phosphorus (mean (SD))	2.94 (63.13)	2
Magnesium (mg) (mean (SD))	97.93 (102.28)	420
Iron (mg) (mean (SD))	55.39 (32.18)	470
Zinc (mg) (mean (SD))	7.84 (4.40)	446
Copper (mg) (mean (SD))	0.96 (0.48)	444
Iodine (µg) (mean (SD))	144.43 (70.80)	429
Manganese (mg) (mean (SD))	1.82 (0.89)	445
Chromium (µg) (mean (SD))	29.73 (17.09)	446
Selenium (µg) (mean (SD))	48.55 (22.60)	446
Molybdenum (mcg) (mean (SD))	22.93 (33.29)	188
Fatty Acids	-	-
n3-long chain polyunsaturated fatty acids (mg) (mean (SD))	48.50 (376.96)	29
n6-long chain polyunsaturated fatty acids (mg) (mean (SD))	0.46 (9.98)	2
n9-long chain polyunsaturated fatty acids (mg) (mean (SD))	0.50 (10.87)	2
Fish oil (mg) (mean (SD))	83.74 (601.47)	31
EPA (mg) (mean (SD))	25.34 (189.57)	34
DHA (mg)(mean (SD))	17.80 (125.25)	34

Supplementary Table S4. Daily estimated intake of prenatal supplements assessed at 24 weeks gestation, with 1 month recall, including vitamins, minerals, and fatty acids, with mean (SD) values and number of participants taking each supplement.

Neurodevelopmental Diagnosis	Model 1 n3-LCPUFA Odds Ratio [95% CI] p-value	Model 2 D vitamin Odds Ratio [95% CI] p-value	Model 3 Prenatal Supplements Odds Ratio [95% CI] p-value	Model 4 Energy Odds Ratio [95% CI] p-value	Model 5 Maternal ADHD genetic risk Odds Ratio [95% CI] p-value	Model 6 Genomic PCs Odds Ratio [95% CI] p-value
All Neurodevelopmental Disorder Diagnosis	1.53 [1.17 - 2.01] (p = 0.002)	1.51 [1.15 - 1.98] (p = 0.003)	1.56 [1.19 - 2.05] (p = 0.001)	1.59 [1.2 - 2.12] (p = 0.001)	1.51 [1.15 - 1.98] (p = 0.003)	1.54 [1.18 - 2.02] (p = 0.002)
ADHD Diagnosis	1.65 [1.21 - 2.26] (p = 0.002)	1.63 [1.19 - 2.24] (p = 0.002)	1.67 [1.22 - 2.29] (p = 0.002)	1.73 [1.25 - 2.44] (p = 0.001)	1.63 [1.19 - 2.24] (p = 0.003)	1.69 [1.23 - 2.35] (p = 0.001)
Autism Diagnosis	2.18 [1.32 - 3.66] (p = 0.002)	2.25 [1.34 - 3.82] (p = 0.002)	2.29 [1.35 - 3.97] (p = 0.002)	2.17 [1.22 - 3.95] (p = 0.009)	2.26 [1.34 - 3.81] (p = 0.002)	2.31 [1.34 - 4.05] (p = 0.003)
Neurodevelopmental Symptom Loads	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**
ADHD Symptom Load (ADHD-RS)	1.76 [1.01 - 2.52] (p < 0.001)	1.73 [0.98 - 2.49] (p < 0.001)	1.78 [1.01 - 2.54] (p < 0.001)	1.76 [0.99 - 2.52] (p < 0.001)	1.68 [0.93 - 2.44] (p < 0.001)	1.78 [1.03 - 2.53] (p < 0.001)
Autism Symptom Load (SRS-2)	3.31 [1.79 - 4.84] (p < 0.001)	3.2 [1.68 - 4.73] (p < 0.001)	3.26 [1.72 - 4.81] (p < 0.001)	3.28 [1.73 - 4.83] (p < 0.001)	3.14 [1.61 - 4.67] (p < 0.001)	3.26 [1.74 - 4.78] (p < 0.001)

Supplementary Table S5. Subanalysis with extra adjustments for the pregnancy Western dietary patterns effect on neurodevelopmental outcomes (multivariable models). **Model 1:** Adjusted for prenatal RCT n-3 LCPUFA. **Model 2:** Adjusted for prenatal RCT high-dose Vitamin D. **Model 3:** Adjusted for prenatal supplements of vitamins, minerals and fatty acids (P1-PC6). **Model 4:** Adjusted for food frequency derived estimated energy intake. **Model 5:** Adjusted for maternal ADHD genetic polygenic risk score **Model 6:** Adjusted for Genomic Principal Components.

	Male Children	Female Children	Interaction
Neurodevelopmental Diagnosis	**Odds Ratio [95% CI] p-value**	**Odds Ratio [95% CI] p-value**	**Estimate [95% CI] p-value**
All Neurodevelopmental Disorder Diagnosis	1.42 [1.02 - 1.99] (p = 0.039)	1.86 [1.15 - 3.07] (p = 0.012)	0.75 [0.44 - 1.26] (p = 0.271)
ADHD Diagnosis	1.45 [0.99 - 2.12] (p = 0.052)	2.48 [1.33 - 4.9] (p = 0.005)	0.6 [0.31 - 1.13] (p = 0.120)
Autism Diagnosis	1.83 [0.96 - 3.32] (p = 0.049)	4.28 [1.09 - 26.98] (p = 0.059)	0.5 [0.13 - 1.52] (p = 0.247)
Parental Questionnaires	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**
ADHD Symptom Load (ADHD-RS)	1.87 [0.72 - 3.02] (p = 0.002)	1.32 [0.4 - 2.25] (p = 0.005)	0.66 [-0.73 - 2.06] (p = 0.353)
Autism Symptom Load (SRS-2)	3.15 [1 - 5.31] (p = 0.004)	2.65 [0.51 - 4.79] (p = 0.016)	0.14 [-2.71 - 2.98] (p = 0.926)

Supplementary Table S6. Sex stratification and statistical interaction effect of the pregnancy Western dietary pattern effect on neurodevelopmental outcomes (multivariable models).

ADHD Diagnosis Subtypes	n=	Odds Ratio [95% CI] p-value	n=	Odds Ratio [95% CI] p-value
ADHD combined presentation (DSM-5)	30/508	1.51 [1.03 - 2.20] (p = 0.033)	-	-
ADHD predominantly inattentive presentation (DSM-5)	25/508	1.71 [1.13 - 2.56] (p = 0.009)	-	-
Neurodevelopmental Symptom Loads	**n=**	**Whole Cohort [95% CI] p-value**	**n=**	**Excluding Neurodevelopmental Disorder Diagnosis [95% CI] p-value**
ADHD-RS Inattention Score	513	0.98 [0.52 - 1.45] (p < 0.001)	428	0.31 [-0.08 - 0.7] (p = 0.124)
ADHD-RS Hyperactivity and Impulsivity Score	509	0.74 [0.38 - 1.11] (p < 0.001)	425	0.34 [0.01 - 0.67] (p = 0.043)
ADHD-RS Total (ADHD Symptom Load)	509	1.73 [0.98 - 2.49] (p < 0.001)	425	0.63 [0.01 - 1.25] (p = 0.048)
SRS-2 Restricted interests and repetitive behaviour Score	513	0.6 [0.26 - 0.94] (p < 0.001)	428	0.15 [-0.13 - 0.44] (p = 0.296)
SRS-2 Social communication and interaction Score	513	2.61 [1.35 - 3.87] (p < 0.001)	428	0.88 [-0.29 - 2.05] (p = 0.143)
SRS-2 Total (Autism Symptom Load)	513	3.21 [1.69 - 4.74] (p < 0.001)	428	1.03 [-0.34 - 2.4] (p = 0.141)

Supplementary Table S7. The pregnancy Western dietary patterns effect on ADHD diagnosis subtypes, and subscores of ADHD and autism symptoms loads (multivariable models). **Column 1**: The entire COPSAC2010 **Column 2**: Subanalysis with any neurodevelopmental disorder diagnosis excluded.

Neurodevelopmental Diagnosis		Univariate Model	Multivariable Model
PC2 Trained in COPSAC2010	**n=**	**Odds Ratio [95% CI] p-value**	**Odds Ratio [95% CI] p-value**
Any Neurodevelopmental Disorder Diagnosis	4069/59725 (6.8%)	1.10 [1.07 - 1.14], p<0.0001)	1.03 [1.00 - 1.07], p = 0.087
ADHD Diagnosis	2764/59725 (4.6%)	1.16 [1.11 - 1.20], p<0.0001	1.07 [1.02 - 1.11], p = 0.002
Autism Diagnosis	1639/59725 (2.7%)	1.06 [1.00-1.11], p=0.030	1.04 [0.98-1.09], p=0.351
PC2 Trained in DNBC	**n=**	**Odds Ratio [95% CI] p-value**	**Odds Ratio [95% CI] p-value**
Any Neurodevelopmental Disorder Diagnosis	4069/59725 (6.8%)	1.10 [1.06 - 1.14], p<0.0001	1.03 [1.00 - 1.07], p = 0.054
ADHD Diagnosis	2764/59725 (4.6%)	1.13 [1.09 - 1.18], p<0.0001	1.05 [1.01 - 1.10], p = 0.018
Autism Diagnosis	1639/59725 (2.7%)	1.06 [1.00-1.11], p=0.020	1.04 [0.99-1.10], p=0.130

Supplementary Table S8. External validation of the association between the pregnancy Western dietary pattern (PC2), trained within COPSAC2010, and within the DNBC and registry derived neurodevelopmental diagnosis in the DNBC cohort.

BIOCHEMICAL	SUPER PATHWAY	SUB PATHWAY	Comp.1 (x 10^-3)	Mediating Metabolite
ergothioneine	Xenobiotics	Food Component/Plant	-3.737	Yes
carotene diol (1)	Cofactors and Vitamins	Vitamin A Metabolism	-3.125	Yes
branched chain 14:0 dicarboxylic acid	Lipid	Fatty Acid, Dicarboxylate	-2.759	Yes
indolepropionate	Amino Acid	Tryptophan Metabolism	-2.533	Yes
1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6)	Lipid	Phosphatidylcholine (PC)	-2.517	Yes
sphingomyelin (d18:2/18:1)*	Lipid	Sphingomyelins	2.226	Yes
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	Lipid	Phosphatidylethanolamine (PE)	2.190	Yes
caprate (10:0)	Lipid	Medium Chain Fatty Acid	2.164	Yes
tartarate	Xenobiotics	Food Component/Plant	-2.155	Yes
3-hydroxystachydrine*	Xenobiotics	Food Component/Plant	-2.054	Yes
caprylate (8:0)	Lipid	Medium Chain Fatty Acid	1.985	Yes
branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1)*	Partially Characterized Molecules	Partially Characterized Molecules	1.948	Yes
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)	Lipid	Plasmalogen	1.900	Yes
pregnen-diol disulfate*	Lipid	Pregnenolone Steroids	1.895	Yes
threonate	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism	-1.885	Yes
hydroxy-CMPF*	Lipid	Fatty Acid, Dicarboxylate	-3.485	No
beta-cryptoxanthin	Cofactors and Vitamins	Vitamin A Metabolism	-3.482	No
3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)	Lipid	Fatty Acid, Dicarboxylate	-3.032	No
2,6-dihydroxybenzoic acid	Xenobiotics	Drug - Topical Agents	-2.912	No
carotene diol (2)	Cofactors and Vitamins	Vitamin A Metabolism	-2.566	No
1-oleoyl-GPG (18:1)*	Lipid	Lysophospholipid	2.494	No
1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6)	Lipid	Phosphatidylcholine (PC)	-2.443	No
pentose acid*	Partially Characterized Molecules	Partially Characterized Molecules	-2.413	No

2-aminophenol sulfate	Xenobiotics	Chemical	-2.377	No
1-arachidonoyl-GPE (20:4n6)*	Lipid	Lysophospholipid	2.363	No
eicosapentaenoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)	-2.338	No
ethyl beta-glucopyranoside	Xenobiotics	Food Component/Plant	-2.267	No
2-hydroxyarachidate*	Lipid	Fatty Acid, Monohydroxy	2.263	No
hippurate	Xenobiotics	Benzoate Metabolism	-2.249	No
3-phenylpropionate (hydrocinnamate)	Xenobiotics	Benzoate Metabolism	-2.248	No
1-oleoyl-GPE (18:1)	Lipid	Lysophospholipid	2.147	No
tartronate (hydroxymalonate)	Xenobiotics	Food Component/Plant	-2.108	No
gamma-CEHC	Cofactors and Vitamins	Tocopherol Metabolism	2.052	No
pregnenetriol disulfate*	Lipid	Pregnenolone Steroids	2.006	No
stachydrine	Xenobiotics	Food Component/Plant	-1.994	No
pyridoxate	Cofactors and Vitamins	Vitamin B6 Metabolism	-1.944	No
1-stearoyl-2-oleoyl-GPC (18:0/18:1)	Lipid	Phosphatidylcholine (PC)	1.943	No
eicosanedioate (C20-DC)	Lipid	Fatty Acid, Dicarboxylate	1.931	No
sphingosine	Lipid	Sphingosines	1.926	No
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4)	Lipid	Phosphatidylcholine (PC)	1.897	No
androstenediol (3beta,17beta) disulfate (1)	Lipid	Androgenic Steroids	1.884	No
cysteine s-sulfate	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism	1.879	No
1-linolenoyl-GPC (18:3)*	Lipid	Lysophospholipid	1.876	No

Supplementary Table S9. The 43 metabolites surviving regularisation in the pregnancy Western dietary patterns sparse partial least squares model in COPSAC2010. Metabolites name, super pathway, sub pathways,loadings for component 1 and whether or not the metabolite significantly mediated the association between the Western dietary pattern and any Neurodevelopmental Disorder Diagnosis.

COPSAC2010 Western Dietary Pattern Metabolite Score Correlation Matrix	Maternal - 24 Weeks Gestation	Maternal - 1 week Postpartum	Child - 6 months	Child - 18 months	Child - 6 years
Maternal - 24 Weeks Gestation	1	0,68	0,42	0,46	0,33
Maternal - 1 week Postpartum	0,68	1	0,38	0,40	0,27
Child - 6 months	0,42	0,38	1	0,3	0,21
Child - 18 months	0,46	0,40	0,30	1	0,39
Child - 6 years	0,33	0,27	0,21	0,39	1
VDAART Western Dietary Pattern Metabolite Score Correlation Matrix	Maternal - 10-18 weeks Gestation	Maternal - 32-38 weeks gestation	Child - 1 year	Child - 3 years	Child - 6 years
Maternal - 10-18 weeks Gestation	1	0,72	0,48	0,35	0,40
Maternal - 32-38 weeks gestation	0,72	1	0,50	0,34	0,41
Child - 1 year	0,48	0,50	1	0,64	0,54
Child - 3 years	0,35	0,34	0,64	1	0,62
Child - 6 years	0,40	0,41	0,54	0,62	1

Supplementary Table S10. Correlation matrices of the respective maternal and child Western dietary pattern Metabolite Scores in the COPSAC2010 and VDAART cohorts.

Cohort Characteristics	COPSAC2010	VDAART	p-value	COPSAC2000	p-value
n =	600	656		348	
Age (years) (mean (SD))	10.3 (0.3)	6.0 (0.1)	<0.001	17.7 (0.6)	<0.001
Male Sex (%)	310 (51.7)	341 (52.1)	0.934	172 (49.4)	0.55
Caucasian Race (%)	573 (95.5)	254 (40.3)	<0.001	339 (97.4)	0.19
Income type (%)			<0.001		<0.001
Low	48 (13.0)	81 (34.9)		90 (26.9)	
Medium	114 (31.0)	78 (33.6)		216 (64.5)	
High	206 (56.0)	73 (31.5)		29 (8.7)	
Maternal Education Attainment at Birth			<0.001		<0.001
Low	46 (7.7)	232 (36.8)		186 (55.9)	
Medium	373 (62.2)	170 (26.9)		94 (28.2)	
High	181 (30.2)	229 (36.3)		53 (15.9)	
Maternal age at birth (years) (mean (SD))	32.4 (4.3)	25.49 (5.42)	<0.001	30.1 (4.6)	<0.001
Maternal Pre-pregnancy Body Mass Index (mean(SD))	24.6 (4.4)	28.5 (7.9)	<0.001	-	-
Birthweight (kilograms) (mean (SD))	3.5 (0.5)	3.3 (0.6)	<0.001	3.5 (0.5)	0.655
Gestational age (days) (mean (SD))	279 (12)	273 (14)	<0.001	282 (11)	<0.001
Caesarean section (%)	125 (20.8)	187 (29.7)	<0.001	74 (21.3)	0.941
Maternal smoking during pregnancy (%)	44 (7.3)	18 (2.8)	<0.001	79 (22.7)	<0.001
ADHD Diagnosis (%) / 6 years (VDAART)	65 (11.0)	18 (2.7)	<0.001	-	-
ADHD Diagnosis (%) / Ever 8 years (VDAART)	65 (11.0)	57 (8.7)	0.213	-	-
ADHD-RS total score (mean(SD))	9.9 (8.7)	-	-	-	-
ASRS total score (mean(SD))	-	-	-	4.1 (3.9)	-

Supplementary Table S11. Cohort characteristics stratified by cohorts. P-values summarise cohort characteristic differences between COPSAC2010/VDAART and COPSAC2010/COPSAC2000 respectively. Low, medium, and high income are defined as *<50,000, 50,000 - 110,000, and >110,000 Euro* in COPSAC2010/COPSAC2000, and *<30,000, 30,000 - 99,999, and >$100,000 USD* in VDAART, respectively. Low, medium and high level educational attainment are defined as "*primary, secondary, or college graduate*", "*tradesman or bachelor's degree*" and "*Masters degree*" in COPSAC2010/COPSAC2000 and "*Did not graduate from high school/Graduated from high school*", "*Technical school/Junior college/some college*" and "*Graduate school/College graduate*" in VDAART.

Neurodevelopmental Diagnosis	Maternal Pre-pregnancy BMI Odds Ratio [95% CI] p-value	Child Sex (Male) Odds Ratio [95% CI] p-value	Child ADHD Polygenic Risk Score Odds Ratio [95% CI] p-value	Child Autism Polygenic Risk Score Odds Ratio [95% CI] p-value
All Neurodevelopmental Disorder Diagnosis	1.04 [0.99 - 1.10] (p = 0.097)	2.74 [1.66 - 4.65] (p < 0.001)	1.50 [1.16 - 1.94] (p = 0.002)	1.30 [1.02 - 1.67] (p = 0.039)
ADHD Diagnosis	1.05 [0.99 - 1.11] (p = 0.102)	3.54 [1.94 - 6.79] (p < 0.001)	1.60 [1.19 - 2.18] (p = 0.002)	1.47 [1.10 - 1.97] (p = 0.009)
Autism Diagnosis	1.13 [1.03 - 1.24] (p = 0.006)	1.90 [0.65 - 6.06] (p = 0.250)	1.45 [0.83 - 2.56] (p = 0.197)	1.44 [0.83 - 2.54] (p = 0.196)
Neurodevelopmental Symptom Loads	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**	**Estimate [95% CI] p-value**
ADHD Symptom Load (ADHD-RS)	0.24 [0.08 - 0.39] (p = 0.003)	4.04 [2.73 - 5.35] (p < 0.001)	1.37 [0.68 - 2.05] (p < 0.001)	1.20 [0.52 - 1.87] (p < 0.001)
Autism Symptom Load (SRS-2)	0.46 [0.15 - 0.78] (p = 0.004)	3.98 [1.31 - 6.65] (p = 0.004)	1.60 [0.19 - 3.00] (p = 0.026)	1.78 [0.40 - 3.16] (p = 0.012)

Supplementary Table S12. Maternal pre-pregnancy BMI and child sex associations on neurodevelopmental outcomes, with the Western dietary pattern included in multivariable models, shows the independent associations of maternal pre-pregnancy BMI and child sex on neurodevelopmental diagnosis and symptom loads. Furthermore, models show the associations with child ADHD and autism polygenic risk scores (PRS), likewise also adjusted for the Western dietary pattern, on neurodevelopmental diagnosis and symptom loads.

	Missingness all metabolites (#1131)		Missingness selected metabolites (#43)	
Neurodevelopmental Diagnosis	**Odds Ratio [95% CI] p-value**	**p-value**	**Odds Ratio [95% CI]**	**p-value**
Any Neurodevelopmental disorder	OR = 1.004 [0.998; 1.011]	0.2	OR = 1.097 [0.848; 1.403]	0.468
ADHD	OR = 1 [0.992; 1.008]	0.923	OR = 0.953 [0.698; 1.273]	0.753
Autism	OR = 1.009 [0.994; 1.023]	0.213	OR = 0.961 [0.516; 1.628]	0.89
Neurodevelopmental Symptom Loads	**Estimate [95% CI]**	**p-value**	**Estimate [95% CI]**	**p-value**
ADHD Symptom Load (ADHD-RS)	B =0.002 [0; 0.005]	0.084	B = 0.028 [-0.064; 0.12]	0.55
Autism Symptom Load (SRS-2)	B = 0.001 [-0.001; 0.004]	0.356	B = 0.013 [-0.078; 0.105]	0.772
Exposure	**Estimate [95% CI]**	**p-value**	**Estimate [95% CI]**	**p-value**
Western Dietary Pattern	B = 0 [-0.003; 0.002]	0.904	B = 0.106 [0.016; 0.196]	0.021

Supplementary Table S13. Analysis of missing metabolites and their association with neurodevelopmental outcomes. Missingness rates of all metabolites and the selected 43 metabolites in the pregnancy Western dietary pattern metabolite score, alongside their odds ratios and confidence intervals for neurodevelopmental disorders, symptom loads and the Western dietary pattern.